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Abstract

Post-Traumatic Stress Disorder (PTSD) and addiction are strongly comorbid. However, the
underlying neural mechanisms by which traumatic memory recall may increase addiction
liability are poorly understood. The inability to suppress memory recall related to either stressful
or rewarding, drug-related experiences may be an underlying neuropsychological feature capable
of triggering both PTSD or addiction-related behaviours. Our previous research has shown that
transmission through dopamine (DA) D4 and D1 receptor subtypes (D4R, D1R) within the
prefrontal cortex (PFC) strongly modulates emotional memory acquisition and recall (Lauzon et
al., 2009). Using olfactory fear conditioning and morphine conditioned place preference (CPP)
procedures in rats, combined with molecular protein expression analyses, we examined if 1)
associative fear memory recall would increase subjects’ sensitivity and vulnerability to morphine
reward salience; 2) if blocking fear memory recall with intra-PFC D1R stimulation may block the
potentiation of morphine reward salience; 3) if PFC D4R stimulation would potentiate morphine
reward salience by modulating the emotional salience of fear memories during memory
acquisition. Furthermore, we concomitantly examined the underlying PFC molecular signaling
pathways associated with these behavioural effects. We report that rats receiving supra-threshold
(0.8 mA) fear conditioning showed strong associative fear memories and heightened morphine
reward sensitivity (with either systemic or intra-ventral tegmental area [VTA] administered
morphine). Inhibition of fear memory recall with intra-PFC D1R activation reduced the
potentiated morphine CPP through cyclic adenosine monophosphate (cAMP) and extracellularsignal-related kinases 1 and 2 (ERK1/2) dependent molecular pathways. In addition, PFC D1R
stimulation selectively increased phosphorylation levels of ERK 1/2. In contrast, PFC D4R
activation bi-directionally controlled fear memory acquisition and morphine CPP behaviours
through a calcium/calmodulin dependent kinase II (CaMKII)-dependent mechanism wherein
D4R activation selectively stimulated phosphorylation of PFC CaMKII. Our findings reveal for
the first time a novel DA-receptor dependent mechanism in the mammalian PFC capable of
controlling both fear-related associative memory formation and the salience of morphine-related
reward memories.

Key words: post-traumatic stress disorder, opioid addiction, medial prefrontal cortex, ventral
tegmental area, dopamine, cAMP, ERK, CaMKII, morphine conditioned place preference,
olfactory fear conditioning, western blot
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1. Introduction
1. 1 Post-traumatic Stress Disorder (PTSD)
PTSD is classified as an axis I anxiety disorder that can develop after individuals
experience repeated or singular traumatic events, typically involving the threat of serious injury,
physical harm or death (Diagnostic and Statistical Manual of Mental Disorders. 5th ed., 2013).
PTSD remains one of the most frequent neuropsychiatric disorders, with a lifelong prevalence in
the US estimated at 8.3%. Approximately 1 in 12 adults will experience PTSD-related symptoms
during their lives (Breslau et al., 1998; Schöner, Heinz, Endres, Gertz & Kronenberg, 2017).
Some professions, such as soldiers, first responders (police, firefighters, etc), are at higher risk of
trauma exposure and subsequently developing PTSD. The symptoms of this disorder are a
complex constellation of symptoms including hyperarousal (sleep disturbances, difficulty
concentrating), behavioural avoidance (diminished participation in activities to avoid people
and/or places that are associated with the traumatic experience), emotional numbing, and reexperiencing phenomena. The hallmark of PTSD symptoms is characterized by intrusive
memory recall of the traumatic event, triggered by exposure to the related cues, typically
associated with intense and prolonged anxiety (DSM 5th Ed, 2013). For example, a veteran could
link the sound of a lawn mower to the sound of a helicopter in the battle field, which in turn
triggers the stressful memory recall and feelings of anxiety. This extreme and sustained
maladaptive response to the stressful events may persist for years, and is often associated with
significant disability and distress (Schöner et al., 2017). The types of stressors can also influence
the likelihood of developing PTSD, as well as the severity of the symptoms. Depending on the
nature of the traumatic event, longer exposure and greater intensity of the experience can
increase the risk for the subsequent development of PTSD. Stressor severity was also the
strongest predictor of symptoms at both 3 and 12 months after trauma exposure (Wolfe, Erickson,
Sharkansky, King & King, 2000). Experiences related to interpersonal assaults, such as rape or
violent combat, have a greater likelihood of causing PTSD compared to events like natural
disasters and/or traffic accidents (Breslau et al., 1998). However, not all individuals that
experience traumatic events will go on to develop PTSD. Brewin, Andrews and Valentine (2000)
summarized the risk factors associated with the later development of PTSD: trauma severity,

2

previous trauma history (such as childhood abuse), comorbid mental disorders, gender, lower
education, introverted personalities, the availability of post-traumatic support services, are all
contributing factors to the development and prognosis of the disorder.
The etiology of PTSD is complex and multifactorial; and the symptoms of PTSD have
been linked to a variety of underlying neuropathological mechanisms (Brewin et al., 2000;
Pizzimenti & Lattal, 2015). Over the past several decades, research has largely shifted attention
from the potential role of the endocrine system, to specific neural circuits which are involved in
fear memory regulation. Currently, PTSD is generally conceptualized as a neural disorder related
to abnormal memory extinction. For example, a significant body of neuroimaging studies have
revealed that PTSD patients show hyperactivity in the amygdala, hypoactivity in the medial
prefrontal cortex (mPFC), and abnormal hippocampal function, when processing stimuli with
negative emotional valence. Due to the inhibitory nature of the PFC projection to the amygdala,
it has been proposed that the re-experiencing of traumatic memories could result from a lack of
inhibition from the PFC to the amygdala (Shvil, Rusch, Sullivan & Neria, 2013; Tipps, Raybuck
& Lattal, 2013). In the review of Shvil et al. (2013), the authors summarized several pieces of
evidence regarding the etiology of PTSD. The authors pointed out that PTSD patients show
deficiencies in processing danger-safety related contextual information compared to trauma
exposed non-PTSD individuals. With the persistent re-experiencing of traumatic memories,
PTSD individuals not only reconsolidate the stressful events, but also maintain the physiological
hyperarousal state which leads to the dysfunction of other physiological systems. Indeed, Shvil et
al. (2013) also pointed out that PTSD patients have distinct abnormal psychophysiological
features, such as heightened resting heart rate, persistent elevated heart rate during exposure to
traumatic stimuli, which is an indication of weakened regulation of psychophysiological
responses. Due to these constant states of anxiety (both psychological and physiological), it is
perhaps not surprising that PSTD patients will often self-medicate with drugs of abuse in an
attempt to relieve their symptoms (Bradizza, Stasiewicz & Paas, 2006).
1. 2 Opiate Addiction
Across the wide range of drugs of abuse, opiate-class drugs represent the most addictive
by producing potent rewarding effects in the early stages of exposure, and the formation of
potent associative memories linked to the drug-taking experience (Hyman, Malenka & Nestler,
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2006). While the initial/early drug exposure phase is generally controlled and voluntary;
compulsive and uncontrolled drug taking is maintained due to the euphoric effects of drugs
combined with a need for withdrawal symptoms alleviation (Everitt et al., 2008). This stage is
concomitant with neurobiological changes in various brain regions, including the prefrontal
cortical areas and subcortical areas, such as the mesolimbic DA system, which in turn can
modify drug-seeking behaviours (Everitt & Robbins, 2005). After repeated drug exposure, fullblown addiction and dependence develops, along with a wide variety of associated
neurobiological and behavioural changes (Everitt et al., 2008). At this stage, drugs exert
controlling power over behaviours, characterized by compulsive drug taking and/or obsessive
craving for the drug of abuse (Hyman et al., 2006). Repeated drug use also results in molecular
and pharmacological neuroadaptions involving tolerance to the drugs rewarding effects, leading
to greater and greater consumption levels in order to achieve the desired hedonic state of reward
(Nestler & Aghajanian, 1997).
Current theories point out the importance of learning and memory dysregulation during
the addiction process, involving maladaptive forms of Pavlovian and instrumental learning
(Hyman et al., 2006). As mentioned previously, drugs of abuse hijack the neural mechanisms
involved in emotional memory formation, such as the mPFC, which controls executive functions
and emotional memory processing (Hyman et al., 2006). Importantly, addicted individuals
usually associate drugs and their euphoric effects with specific, associative environmental cues.
Re-encountering these cues can then elicit drug-related memories, which in turn can trigger
compulsive drug seeking behaviours and relapse.
Opioids are currently the most effective analgesics for clinical pain management.
Nevertheless, there is currently a national and international opioid addiction epidemic due to the
wide spread availability of both prescription and illicit forms of opiate-class compounds and a
concomitant dramatic rise in opioid-related overdose deaths (Popova, Patra, Mohapatra, Fischer
& Rehm, 2009). According to the International Narcotic Control Board (2006), Canada ranked
first (in per capita use) for consumption of hydromorphone, second in morphine and oxycodone
use and third in hydrocodone use. In 2003, there were an estimated 321,000-914,000 abusers of
non-medical prescription opioids. This number has increased 24% from 2002 to 2005 (Popova et
al., 2009). Based on the OPICA study conducted in five Canadian cities (Vancouver, Toronto,
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Montreal, Edmonton and Quebec City, Fischer et al., 2005), 48.9% of addicts are non-medical
prescription opioid users, 27.8% are using illicit heroin, and 23.2% combine opioid drugs with
other classes of drugs. However, recreational opioid abuse is most likely underestimated due to
the clandestine nature in which these drugs are consumed and reported, both in Canada and
globally (Fischer et al., 2005; Popova et al., 2009).
Opioid drugs produce potent euphoric effects and have exceptionally high abuse liability.
Long term exposure results in both psychological and physical dependence. Withdrawal leads to
emotional and motivational symptoms, such as anhedonia, dysphoria and craving. Unlike other
classes of drugs, such as psychostimulants, opioid withdrawal also results in a series of physical
symptoms: hypertension, abdominal pain, flu-like symptoms, tremor and possibly death (Hyman
et al., 2006).
A tremendous body of research has identified many of the neuronal mechanisms involved
in opioid addiction. Endogenous and exogenous opioid molecules bind the mu opioid receptor
subtype (MOP), which are widely spread in the brain and highly concentrated in the ventral
tegmental area (VTA, Fields & Margolis, 2005), which is the origin of mesocorticolimbic
dopamine (DA) pathway (Missale, Nash, Robinson, Jaber & Caron,1998). The MOP is
inhibitory in nature and usually located on the terminals of GABA interneurons in the VTA;
once activated by opioids, the VTA MOR can inhibits GABA inhibitory effects on DA neurons
in the VTA (Fields & Margolis, 2005). In other words, MOP activation disinhibits the inhibitory
effects of GABA neurons on VTA DA neurons, thereby indirectly increasing activity of the
mesocorticolimbic DA pathway. Since increased VTA DA activity is associated with the
processing of reward-related motivational information, one potential mechanism underlying the
rewarding and addictive properties of opioids is by increasing DA transmission to other limbic
areas during drug use (Everitt et al., 2008; Fields & Margolis, 2005; Hyman et al., 2006).
Substantial research has demonstrated the critical role of the VTA in opioid addiction. For
example, Olmstead and Franklin (1997) have reported that intra-VTA morphine administration
elicited drug seeking behaviours, but this effect was not observed following morphine infusions
into other brain regions, such as the amygdala and hippocampus. Blocking the MOP in the VTA
has been shown to impair drug seeking behaviours and mice with MOP gene knock-out in the
VTA show impaired heroin conditioned place preference (CPP, Zhang et al., 2009).
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Although the VTA is believed to mediate the initial rewarding effects of opioids, it is not
responsible for the perception of craving during the withdrawal period. Rather, the increased DA
activity in the PFC has been proposed to encode drug relate associative memory and other
emotional salient information (Lauzon, Bishop & Laviolette, 2009; Laviolette, Lipski & Grace,
2005; Sun et al., 2011)
1.3 PTSD is highly comorbid with addiction
The high rate of comorbidity between PTSD and addiction was first reported in the early
80s with the study of veterans. Kulka et al. (1988) and Keane and Kaloupek (1997) reported that
in Vietnam veteran PTSD patients, 64-84% of them met life time criteria for alcohol abuse and
40%-44% were comorbid with other drugs of abuse. In the following decades, similar results
were also detected in civilian populations. Jacobsen et al. (2001) reviewed and summarized
recent epidemiological studies in the general PTSD population, in which the life time prevalence
of addiction at 22%-43%, was far higher than the prevalence of substance abuse disorder alone
(8.1%-24.7%). Vice versa, whereas the prevalence of PTSD in the general population is 8.3%,
this reaches 36%-50% when patients are sampled from substance abuse treatment centers.
Addiction comorbid with PTSD predicted faster relapse rates and worse treatment outcomes of
substance abuse, with the severity of re-experiencing symptoms as a significant predictor of
relapse (Bradizza et al., 2006). Pre-clinical animal research has found similar effects and shown
that various type of stressors, such as food restriction, social stress or foot shock, can increase
the consumption of heroin, morphine and alcohol tested in self-administration and CPP
paradigms (Edwards et al., 2013; Ribeiro Do Couto et al., 2006; Shalev, 2012).
Thus, both clinical and pre-clinical evidence demonstrates that subjects experiencing
PTSD-related symptoms are at higher risk of developing a substance use disorder and more
likely to relapse to drug abuse. Drug abusing individuals have a reported elevated risk to develop
PTSD when encountering traumatic experiences as compared to non-addicted individuals
(Bradizza et al., 2006; Brady et al., 2009; Jacobsen et al 2001; Pizzimenti & Lattal, 2015;
Steward, Pihl, Conrod & Dongier, 1998). Stewart et al. (1998) and Brady et al. (2009)
summarized the possible reasons for the high comorbidity between PTSD and addiction. First, it
is possible that the influence of drugs increases the probability of experiencing trauma (such as,
higher traffic accident rates during alcohol intoxication). Second, chronic drug abuse or
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withdrawal may lead to elevated anxiety levels, which predisposes individuals for the
development of PTSD when exposed to traumatic events. Third, PTSD patients are more likely
to abuse drugs in order to relieve the symptoms, such as avoiding the vivid reoccurrences of the
traumatic experiences. For example, CNS depressants such as heroin or alcohol acutely relieve
the anxiety arousal symptoms. Fourth, drug abuse may exacerbate and prolong the PTSD
symptoms by interfering with neuronal circuits regulating associative emotional memory
processing. Fifth, some drug withdrawal symptoms may overlap with the PTSD symptoms; for
example, withdrawal from alcohol is accompanied with increased anxiety, sleep disturbance and
irritability, all of which resemble certain PTSD symptoms. In this case, patients may misinterpret
the withdrawal symptoms as a sign of anxiety, thus further increasing the arousal level and
attempts to self-mediate with drugs of abuse. Lastly, stress and anxiety may modulate the
rewarding salience of drugs, thereby influencing relapse to drug taking in drug-dependent
individuals (Liu & Weiss 2002).
Behaviourally, both disorders are characterized by the inability to suppress and
extinguish persistent associative memories linked to either catastrophic events in the case of
PTSD or drug-related rewarding experiences in addiction. In either case, the spontaneous
memory recall related to these experiences maybe an underlying neuropsychological feature
triggering anxiety in the case of PTSD, or relapse/drug seeking in addiction (Lauzon et al., 2013).
In addition, both traumatic and addiction-related associative memories are extremely resistant to
extinction. The recall of the memory is usually associated with specific environmental triggers,
suggesting that abnormal encoding and recall of emotional memory is a key component
underlying the neurobiological etiology of both PTSD and addiction (Pizzimenti & Lattal, 2015).
As noted above, the high comorbidity and symptom overlap between addictive
behaviours and PTSD would suggest a common neurobiological mechanism responsible for the
aberrant memory processing in PTSD and addiction. Indeed, as will be discussed next, research
targeting emotional associative memory neural circuits has yielded a wide body of compelling
evidence, identifying the mammalian PFC as a critical neural region underlying the pathology of
both PTSD and addiction (Pizzimenti & Lattal, 2015, Sun et al., 2011, Lauzon et al., 2013).
1.3a Role of the prefrontal cortex (PFC) in emotional memory regulation
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Converging clinical and pre-clinical evidence has identified the PFC as a brain region
that plays a key role in the acquisition, encoding, recall and extinction of aversive and rewarding
emotionally salient associative learning and memory (Laviolette et al., 2005; Lauzon et al., 2009;
Morgan, Romanski & LeDoux, 1993; Shin & Liberzon 2010; Sun et al., 2011). For example,
stimulation of the DA receptors directly in the mPFC during fear-related memory encoding and
recall stages impaired rats’ ability to acquire and express associative fear memories (Lauzon et
al., 2009). In vivo electrophysiological evidence has also indicated that at the single neuron level,
neurons in the mPFC processed and encoded associative learning of olfactory cues and aversive
stimuli. Laviolette et al. (2005) reported that mPFC neurons show associative responding to fearrelated cues, both in terms of increased associative firing and bursting rates following fearrelated cue presentations. Earlier studies using mPFC lesions and more recent
electrophysiological studies have revealed the vital importance of this area in fear extinction. For
example, PFC lesioned rats showed impaired extinction of conditioned fear (Morgan et al., 1993);
Milan and Quirk (2002) reported increased PFC neuronal activity during extinction learning to
auditory cues previously paired with foot shocks. Inhibition of the PFC attenuated the recall of
conditioned fear and subjects with lesion in the same brain area took significantly longer to
extinguish fear memories and recovered faster when the cue was paired with the aversive stimuli
again (Quirk, Likhtik, Pelletier, & Paré, 2003; Quirk, Russo, Barron & Lebron, 2000). Similar
results have been found in human subjects. For example, one fMRI study found activation of
ventromedial PFC during the extinction phase of fear conditioning, with this regional activation
positively correlated with memory extinction magnitude (Milad et al., 2007).
In the context of addiction, the mPFC is crucially involved in processing drug related
rewarding memory and activation of neuronal circuits in this area elicits drug craving and drug
seeking in humans and other animals (Daglish et al., 2001; Sun et al., 2011, Gholizadeh et al.
2013; Rosen et al., 2016). In vivo electrophysiological evidence from Sun et al. (2011) reported
significant increase of associative mPFC neuronal firing rates during the memory acquisition
phase of morphine CPP. Luo et al. (2004) found that heroin priming injection induced blood
oxygen level-dependent (BOLD) signal changes primarily in the PFC region in rats. Similar
evidence has been reported from human research showing that the presence of drug related cues
elicited subjective craving in abstinent individuals, with a concomitant strong increase in PFC
BOLD signal activity (Daglish et al., 2001; Langleben et al., 2008; Yang et al., 2009). Goldstein

8

and Volkow (2002) summarized that, in human studies, most results showed the activation of the
PFC at the drug intoxication stage, associated with the subjective perception of intoxication.
These authors also reported increased levels of brain activation, such as glucose metabolism, in
the PFC during drug abstinence, and the changes significantly correlated with exposure to drug
cues. Therefore, proper recall and extinction of rewarding and aversive memories requires
optimal PFC function and malfunction of the PFC could impair the extinction of drug-related
memories, resulting in persistent and inappropriate memory recall.
The experiencing of trauma does not fully explain the occurrence of PTSD, in fact, the
exposure and vivid re-experiencing of the catastrophic events may trigger a cascade of
neurobiological sequelae that ultimately lead to the development of PTSD (Segman et al., 2002).
Increasing evidence from animal and human research has shown that stress exposure leads to
malfunction of the PFC with disrupted neuronal functions, accompanied by morphological
abnormalities of the PFC in PTSD patients (Knox, Perrine, George, Galloway & Liberzon, 2010;
Richert, Carrion, Karchemskiy & Reiss, 2006; Wang et al., 2016). Rauch et al., (2003) reported
patients with phobia have increased cortical thickness compared to healthy controls. Furthermore,
Richert et al. (2006) revealed significantly increased gray matter volume in middle and ventral
PFC, but decreased volume in dorsal PFC, which was correlated with increased functional
impairment in PTSD patients. Wang et al. (2016) reported that PTSD patients have hypoactivity
in the dorsal mPFC; but hyperactivity in the ventral mPFC, which corresponds to the grey
matter volume changes in the previous study. In a review by Shin and Liberzon (2010), the
authors pointed out that compared to healthy subjects, PTSD patients showed reduction of PFC
activities during emotional word retrieval.
Brady et al. (2009) pointed out that addiction, PTSD and traumatic brain injury (TBI)
often occur simultaneously, and it is especially true in veterans, which suggests that
neurobiological deficits associated with one disorder may predispose individuals to the other.
Another study found that TBI increases the probability of relapse to alcohol abuse and that the
neurotoxic effects of alcohol interact with TBI, which in turn predicted worse recovery outcomes
(Jorge et al., 2005).
The mammalian PFC regulates higher levels of cognitive function, such as decision
making, behavioural flexibility and emotional regulation. PFC damage is associated with poorer
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executive performance and less behavioural inhibitory control. Drug abuse is known to impair
PFC function (Goldstein & Volkow 2002). For example, Liu, Matochik, Cadet and London
(1998) and Franklin et al. (2002) reported decreased PFC volume and reduction of grey matter in
cocaine, alcohol and heroin abusers. In an animal study, Robinson et al. (2001) reported that
psychostimulant abuse was associated with increased numbers of dendritic branching and
dendritic spine density in the PFC. During states of drug withdrawal, lower brain metabolism
was detected in the PFC region in cocaine and alcohol abusers compared to healthy controls
(Goldstein & Volkow 2002). To summarize, the impairment of PFC function further interferes
with the ability to regulate emotional memory, and to assign appropriate emotional salience to
incoming environmental stimuli. This cascade of events may lead to a pathological cycle,
thereby increasing susceptibility to the development of other psychiatric disorders, such as PTSD
or depression.
1.3b Dopamine transmission in PTSD and addiction
The neurotransmitter DA has received considerable research attention due to its vital role
in the control of emotion, cognition, locomotion, reinforcement, as well as neuroendocrine
secretion. There are two types of DA receptor: the D1 like receptor, which includes D1 (D1R) and
D5 (D5R) subtypes; the D2 like receptor type, which includes D2 (D2R), D3 (D3R) and D4 (D4R)
subtypes. Each type of receptor is involved in different functions, as well as interacting with
other neurotransmitter systems (Messale et al., 1998). D1R is the most widespread DA receptor
in the brain, whereas the D4R is primarily expressed in the frontal cortex, amygdala and
hippocampus. The experiments conducted in this project, the role of DA in emotional memory
regulation is studied with a focus on the mesocorticolimbic pathway, comprising DAergic
projections from the VTA to the nucleus accumbens and PFC. Pharmacologically, my
experiments focus selectively on the D1R and D4R since our lab has previously implicated their
roles in the modulation of emotional associative learning and memory and opiate addiction
(Lauzon et al., 2009; 2013; Lauzon & Laviolette, 2010; Sun et al., 2011).
In the context of addiction, the mesocorticolimbic DA pathway mediates the initial
hedonic effects of drugs by increasing DA transmission in the VTA and associated regions like
the nucleus accumbens and PFC (Fields & Margolis 2005; Volkow, Fowler, Wang, Baler &
Telang, 2009). VTA DA cells are activated in response to emotionally salient stimuli and drugs
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of abuse will thereby increase attention and arousal as well as facilitate conditioned learning and
motivation associated with the drug taking experience. Chronic drug use results in higher levels
of DA transporter activity and increases the thresholds required for dopamine cells to fire, which
leads to a reduced rewarding salience of natural reinforcers as well as escalated levels of drug
abuse to compensate the anhedonia and dysphoric conditions associated with dependence and
withdrawal (Volkow, Fowler, Wang & Goldstein, 2002). This DAergic hypoactivity is believed
to contribute to impaired PFC functions, thus leading to less behavioural inhibition, poor
decision making and dysregulated emotions. Drug-related cue exposure triggers craving and
increases DA transmission in the PFC, which increases the motivation to pursue drugs (Volkow
et al., 2009). Pre-clinical research has indicated the importance of DA transmission in addiction;
for instance, D1R gene knock out mice did not reinstate cocaine self-administration after drug
priming; similarly, blocking mPFC D1R impaired recall of morphine rewarding memory in the
CPP paradigm. In contrast, mPFC D2 receptor activation enhanced cocaine self-administration
and alterations in the expression and function of D1R and D2R were found in the PFC and
amygdala of chronic heroin exposed rats (Caine et al., 2007; Lauzon et al., 2013; Rosen et al.,
2016; Self, Barnhart, Lehman, & Nestler, 1996). Compared to wild type controls, D4R gene
knock out mice showed locomotor super sensitivity to major psychostimulants and ethanol but
decreased reward sensitivity to methamphetamine and amphetamine (Katz et al., 2003;
Rubinstein et al., 1997; Thanos et al., 2010).
Current theories have suggested that D1R transmission is important in memory
preservation and recall over temporally delayed periods (Seamans & Yang, 2004). Zahrt, Taylor,
Mathew and Arnsten (1997) and Lauzon et al. (2009) showed that pharmacological suprastimulation of mPFC D1R blocked the ability of rodents to recall fear memories and impaired
spatial working memory without interfering the encoding and acquisition of the memory.
Interestingly, blockade of mPFC D1R, but not D2R, impaired the ability to use spatial cues in a
previously learned spatial memory task (Seamans, Floresco & Phillips, 1998). Therefore, the
function of mPFC D1R produces an inverted U shape, with either hypo or hyper stimulation
resulting in malfunction in memory recall and PFC dysfunctions. Thus, optimal levels of mPFC
D1R activity are required to regulate emotional memory and adaptive behavioural responses to
environmental stimuli (Seamans & Yang, 2004; Zahrt et al., 1997).
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The D4R is very well characterized from a behavioural and pharmacological perspective
and considerable evidence has indicated that the function of D4R is associated with the
acquisition and encoding of emotionally salient memory (Lauzon et al., 2009; Lauzon &
Laviolette, 2010). For example, in fear conditioning procedures, local mPFC infusion or
systemic injection of a D4R antagonist produced anxiolytic effects, and prevented the association
of cues paired with foot shocks, as well as impaired the acquisition of aversive associative
memories (Inoue, Tsuchiya & Koyama, 1994; Shah, Sjovold & Treit, 2004). Recent research has
further illustrated that mPFC D4 transmission bi-directionally controls associative fear memory
learning depending on the salience of emotional conditioning stimuli (Lauzon et al., 2009).
Specifically, within the hypoactive mPFC (during states of low PFC neuronal activity), D4R
activation potentiated the acquisition of normally non-salient fear conditioning stimuli; while in
the hyperactive mPFC (during states of high PFC neuronal activity), D4R activation impaired the
acquisition of normally supra-threshold fear conditioning stimuli. This finding demonstrated that
D4R regulates the learning and encoding of emotionally relevant sensory input from the
environment, as well as processing the emotional amplitude of incoming sensory information
(Lauzon & Laviolette, 2010). As mentioned above, PTSD and addiction are both characterized
by being unable to inhibit emotional memory recall, which might implicate the involvement of
cortical DA transmission in both disorders.
In terms of DA abnormalities in PTSD, early studies reported higher levels of urinary and
plasma DA in PTSD patients (Hamner & Diamond, 1993; Yehuda, Southwick, Giller, Ma &
Mason, 1992). Genetically, Comings, Muhleman and Gysin (1996) found that carrying the D2
A1 allele significantly increases the susceptibility to the development of PTSD after trauma
encounters in veterans, as well as being positively correlated with symptom severity.
Interestingly, the high prevalence of the D4R genotype was also detected in alcohol abusers, and
associated with the severity of alcoholism (Coming, Muhleman, Ahn, Gysin & Flanagan, 1994).
More recent studies have reported that a variable number tandem repeat (VNTR) polymorphism
found in the DA transporter gene is frequently associated with PTSD patients compared to nonPTSD trauma survivors (Segman et al., 2002). Dragan and Oniszczenko (2009) reported that the
longer repetition (7-8 repeat) of a VNTR polymorphism located on the exon III of D4R gene was
frequently associated with more intense PTSD symptoms and an over-sensitivity to negative
emotional stimuli. Interestingly, this long repetition polymorphism was also detected exclusively
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in opiate dependent individuals based on patient samples from China and Israel (Kotler et al.,
1997; Li et al., 1997). Shao et al. (2006) further reported that D4 VNTR long allele carriers
displayed higher levels of craving for heroin after exposure to drug-related cues, as well as with
severe physical dependence; early onset and higher levels of craving in alcohol abusers (Hill,
Zezza, Wipprecht & Neiswanger 1999; Hutchison, McGeary, Smolen, Bryan & Swift, 2002).
Together, this evidence may suggest a common genetic abnormality of the DA D4R system
associated with both PTSD and opiate addiction vulnerability.
1.3c Downstream molecular pathways of DA receptor transmission involved in PTSD and
addiction
D1R stimulation links to the activity of an important downstream signaling molecule,
cyclic adenosine monophosphate (cAMP), which is critically involved in major intracellular
signalling pathways. Ligand binding to D1R activates the receptor’s G-protein, which then
converts ATP to cAMP. cAMP next activates the protein kinase A (PKA) phosphorylation
process, ultimately leading to the phosphorylation of various intracellular proteins and regulation
of downstream neurobiological responses which in turn can modify a number of behaviours
(Dwivedi & Pandey 2008).
Interestingly, over the last several decades, several studies have found linkages between
cAMP activity states and both PTSD and addiction. For example, one clinical study (Lerer,
Ebstein, Shestatsky, Shemesh & Greenberg, 1987) found PTSD patients have lower levels of
cAMP, suggesting that abnormal cAMP levels may serve as a bio-marker for the diagnosis.
Similarly, in rodents, cAMP inhibition in the amygdala or the mPFC blocked fear memory
consolidation and interfered with long term memory formation tested in an auditory fear
conditioning paradigm (Schafe & Ledoux 2000). Lauzon et al (2012) reported that the effects of
PFC D1R activation on the attenuation of fear or reward memory recall is cAMP dependent and
that inhibition of this pathway reversed the effects of PFC D1R stimulation on memory recall.
Similar effects were also observed in cocaine self-administration and lever pressing for food in
rats; in both paradigms, inhibition of cAMP/PKA in the nucleus accumbens (NAc) attenuated
lever pressing for rewards; while activation of cAMP facilitated these behaviours (Baldwin,
Sadeghian, Holahan & Kelley, 2002; Self et al., 1998). Furthermore, the effects of cAMP on
reward memory processing are not limited to the recall phase, but also the acquisition of the
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reward memory. Beninger, Nakonechny and Savina (2003) and Sutton, McGibney and Beninger
(2000) have reported that cAMP inhibition during the conditioning phase attenuated the learning
of amphetamine associated rewarding effects and amphetamine-induced locomotion.
D1R activation is also closely linked to the extracellular-signal-related kinases 1 and 2
(ERK1/2), which is a neuronal molecular pathway highly involved in several types of synaptic
plasticity, learning and memory and the processing of drug-related reward behaviours (Rosen,
Sun, Rushlow & Laviolette, 2015; Valjent, Pagès, Hervé, Girault & Caboche, 2004) as well as
aversive memory processing (Cestari, Rossi-Arnaud, Saraulli & Costanzi, 2014). Recent PTSD
research has revealed several roles for the ERK pathway in emotional memory processing
(Cestari et al., 2014). For example, Ardi, Ritov, Lucas and Richter-Levin (2014) and Jeon et al.
(2012) reported that rats re-exposed to a stress-related environment showed significantly higher
ERK activation levels, and PTSD-like symptoms, suggesting that the ERK pathway is involved
in conditioned fear memory recall. Furthermore, the ERK pathway is critical for memory
extinction and consistent increases in phosphorylated ERK2 (pERK 2) levels in the PFC have
been detected during fear extinction learning in mice (Cestari et al., 2014; Matsuda et al; 2015);
similarly, Fischer et al. (2007) have reported that ERK1/2 shows increased phosphorylation
levels in fear memory extinction trials. Thus, ERK signaling is required for the acquisition, recall
and extinction of cue-related conditioned fear and is similarly involved in processing drug
related reward memory (Gholizadeh et al; 2013; Lysons et al., 2013; Rosen et al., 2015 & 2016).
ERK is an important molecular substrate by which drugs may exert their effects by
modulating the phosphorylation of ERK through a D1R transmission-dependent mechanism
(Valjent, Corbille, Bertran-Gonzales, Herve & Girault, 2006; Valjent et al., 2004). For example,
an in vitro study using SH-SY5Y cells revealed that acute treatments with morphine or other
opioids stimulated the phosphorylation of ERK1/2. However chronic opiate exposure was shown
to reduce these phosphorylation levels (Bilecki et al., 2005). Antagonizing D1R transmission
reverses the effects of several drugs, such as ethanol and cocaine, on ERK phosphorylation in the
mPFC and the NAc (Acquas et al., 2010; Fricks-Gleason & Marshall, 2011; Ibba et al., 2009). In
addition, D1R activation increased phosphorylation of ERK1/2 in the mPFC and striatum which
demonstrated a close functional connection between D1R transmission and ERK signalling
during substance abuse (Xue, Mao, Jin & Wang, 2015). ERK is also highly associated with the
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formation and the consolidation of associative morphine reward memory. For example, mice
with ERK gene knock out exhibit deficient reactions to morphine and inhibition of ERK was
shown to attenuate previously formed morphine CPP memories (Mazzucchelli et al., 2002;
Valjent et al., 2006). Gholizadeh et al. (2013) have demonstrated that ERK inhibition in the
basolateral amygdala (BLA) or the mPFC blocked recent and remote morphine reward memory
recall, accompanied by a reduction of pERK in the BLA and increased pERK in the PFC
following chronic opiate exposure (Lyons et al; 2013; Rosen et al., 2016).
As discussed previously, D4R- mediated transmission in the PFC regulates emotional
memory acquisition, and this process requires the participation of calcium/calmodulin dependent
kinase II (CaMKII, Lauzon et al., 2012), a molecule critically involved in synaptic plasticity, as
well as learning and memory (Frankland, O'Brien, Ohno, Kirkwood & Silva 2001; Silva, Paylor,
Wehner & Tonegawa 1992). In vitro studies have shown that activation of PFC D4R bidirectionally regulates the levels of CaMKII. Specially, during high cortical neuronal activity
states (corresponding to states of high emotional arousal/salience), D4R activation induced
dramatic reductions in local CaMKII activity. This mechanism requires the reduction of protein
kinase A (PKA), leads to increased protein phosphotase-1 (PP1) levels and ultimately
dephosphorylates and reduces the activity of CaMKII (Gu & Yan, 2004). Whereas during low
neuronal activity states (corresponding to low emotional arousal/salience), D4 activation
stimulates phospholipase C, which results in an increased intracellular calcium (Ca2+)
concentration, subsequently promoting calmodulin to bind the kinase and phosphorylate CaMKII
to its activated state, phosphorylated CaMKII (pCaMKII, Gu & Yan, 2004). In vivo studies
examining the role of CaMKII have reached agreement with the previous in vitro research. For
example, Lauzon et al. (2012) reported that in subthreshold fear conditioning, which resembles
the lower baseline neuronal activities, CaMKII inhibition reverses the effects of D4R activation
on facilitation of fear memory learning. While in supra-threshold fear conditioning, which is the
analogy of higher neuronal activity states, blocking CaMKII activity by stimulation of
PKA/inhibition of PP1 rescues the effect D4R stimulation on attenuating conditioned fear
acquisition.
CaMKII expression is more concentrated in the forebrain; once activated, it is
translocated to post synaptic sites concomitant with increasing AMPA and decreasing NMDA
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receptor activity though a D4-dependent mechanism (Gu, Jiang, Yuan & Yan, 2006; Wang,
Zhong & Yan, 2003). Given the well-established role of AMPA and NMDA receptors in
learning and memory, as well as their involvement in psychiatric disorders, such as
schizophrenia, it is not surprising that aberrations in CaMKII signalling is correlated with various
behavioural and neurobiological impairments (Lauzon & Laviolette, 2010). Indeed, in vivo
research has shown that mice with a CaMKII gene knock out display deficiencies in spatial
learning and long term spatial memory retrieval (Silva et al 1992). CaMKII gene deficient mice
also showed slower learning of foot shock and lower behavioural responses to fear-related cues
(Chen, Rainnie, Greene & Tonegawa, 1994). CaMKII transduction also dynamically affects the
ability of subjects to attribute reward learning at different drug exposure stages. In drug-naïve
subjects, consolidation of morphine reward memories required BLA CaMKII signaling whereas
the recall of long term opiate rewarding memory involves PFC CaMKII signaling (Gholizadeh et
al., 2013). Chronic exposure or withdrawal to opiates was shown to cause a dramatic reduction in
BLA CaMKII-α levels concomitant with increasing CaMKII-α levels in the mPFC (Lyons et al.,
2013; Rosen et al., 2016). Thus, CaMKII signaling linked to the D4R, is involved importantly not
only in fear-related memory processing, but also in the opiate addiction and memory formation
process.
1.4 Pre-clinical animal modelling of PTSD
PTSD is a devastating disorder with high prevalence and considerable functional
disability. Thus, there is an urgent need for a better understanding of the underlying
neurobiological mechanisms of PTSD. Over several decades, a rich variety of pre-clinical rodent
models have been developed to help gain further insights into this disorder (Schöner et al, 2017).
The establishment of an effective pre-clinical animal model should follow 3 criteria, as proposed
by Willner (1984): first, face validity: the probed symptoms should resemble those of the
modelled disorder. Second, construct validity: the animal model should mimic similar underlying
neurobiological mechanisms as those observed in the human patient. Third, predictive validity:
the animal model should enable the researcher to make accurate predictions about the treatment
effects.
In terms of pre-clinical animal PTSD models, this paradigm should have a fear stimulus,
which generates stressful behaviours similar to the symptoms of PTSD. The stressor induced
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PTSD-like symptoms should be acute and intensive instead of mild and chronic (Yehuda &
Antelman, 1993). More importantly, the hall mark of PTSD is the re-experience symptom
associated with traumatic memories and therefore the stress related cues/environments should be
able to elicit anxiety and cause memory recall of the traumatic experience. Today, the most
accepted pre-clinical animal model for modelling PTSD-like symptoms is the fear conditioning
assay (Ross et al., 2017). In terms of construct validity, the neural circuitries involved in fear and
anxiety in rodent and the etiology of PTSD in humans are similar, and are highly conserved
throughout evolution, including brain areas like the PFC and amygdala (Ross et al., 2017).
However, the neurobiological underpinnings of PTSD are far from being understood, and there
are currently no effective pharmacological treatments for PTSD, making it difficult to establish
clear construct and predictive validities (Schöner et al, 2017).
Associative fear conditioning using foot shock as a proxy for a traumatic experience, has
been wildly employed to study anxiety disorders and PTSD in pre-clinical research, primarily
using rodents (Van Dijken, Van der Heyden, Mos & Tilders, 1992). In general, this simple,
Pavlovian conditioning paradigm requires confining the animal in an inescapable chamber where
foot shock can be delivered, allowing for variation in the duration and the intensity of the
stimulus. Foot shock models elicit long lasting behavioural effects and associative memories
persisting up to 3 weeks (Van Dijken et al, 1992), and it can induce core symptoms of PTSD,
such as anxiety, avoidance and hyperarousal, as foot shocked rodents will demonstrate long
lasting increased immobility, decreased rearing and grooming behaviours in various tests, such
as open field and the elevated plus maze (Pynoos, Ritzmann, Steinberg, Goenjian & Prisecaru,
1996; Van Dijken et al, 1992). One advantage of foot shock fear conditioning models is that they
enable researchers to model the re-experiencing symptoms by associating shocks with
associative cues (such as tone, context, lights or odours) during the memory acquisition, while
presenting the cues alone (without the shock) later during the test phase to elicit the recall of the
associative fear memory and evoke PTSD-like anxiety behaviours (Pynoos et al., 1996; Van
Dijken et al, 1992; Lauzon et al., 2009). Thus, consistent with the extant literature, my studies
employed a well-established model of olfactory fear conditioning in rats combined with
morphine reward conditioned place preference, in order to simultaneously model both PTSD and
addiction-like behaviours.
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1.5 Research Objectives and Hypotheses
The role of D1R and D4R transmission within the mammalian PFC, as well as their associated
downstream molecular signaling pathways in fear-related and opiate rewarding associative
memory processing have been previously identified (Lauzon et al., 2009, 2012, 2013; Rosen et
al., 2016). However, the possible relationship between intra-PFC DAergic modulation of fearrelated memory and how this may modulate reward-related memory processing has not
previously been investigated. Although previous research has suggested that stress itself can
reinstate drug taking behaviours, it does not fully explain the high comorbidity between PTSD
and opioid addiction phenomena and does not explain how the recall of a traumatic memory
might influence sensitivity to reward-related, drug-induced memory formation. Our overarching
hypothesis is that DAergic transmission within the PFC, by modulating the salience and recall
of traumatic, fear-related associative memories, may similarly modulate the ensuing increased
sensitivity to opiate-related reward salience and represent a mechanistic link between PTSD
and drug addiction comorbidity. More specifically, we hypothesized that PFC D4R stimulation,
by selectively increasing the emotional salience of normally non-salient fear memories during
memory acquisition, may simultaneously increase sensitivity to the rewarding effects of opiates,
measured in conditioned place preference procedures. In contrast, PFC D1R stimulation, by
selectively blocking the recall of previously acquired associative fear memories, might
simultaneously block the potentiation of morphine reward salience. For this thesis, my specific
experimental AIMS were the following:
1) Determine whether fear memory recall potentiates sensitivity to morphine’s
rewarding effects; and if so:
2) Determine the selective roles of intra-PFC D1 and D4 receptor transmission during
the acquisition vs. recall phases of associative fear memory formation.
3) Determine if intra-PFC D1 vs D4 modulation of associative fear memory formation
modulates sensitivity to the rewarding effects of morphine.
4) Determine the downstream molecular pathways associated with intra-PFC D1R vs.
D4R modulation of fear memory and morphine reward sensitivity, focusing on the
cAMP, ERK 1/2 and CaMKII signaling pathways.
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2. Materials and Methods
This project involved 20 independent experimental groups, each consisting of 6-10 adult
male Sprague-Dawley rats (Charles River, Canada). This section describes the materials and
methods including surgery and drug treatment, behavioural and western blot protocols, and
histology and data analysis.
2.1 Animals and surgery
Male Sprague Dawley rats (weight 300 g to 350 g) were purchased from Charles River
Laboratories and housed in temperature-controlled (21 °C) room with free access to food and
water through out the duration of the experiments. Animals were pair housed before the surgery;
and were individual housed after the surgery and during entire experiments in clear Plexiglas
cages covered with rat bedding; cages were changed on weekly basis by animal care staff. All
procedures were performed at the University of Western Ontario (London, Ontario, Canada) and
adhered to regulations outlined by the Canadian Council on Animal Care. The animals were
anesthetized using a mixture of ketamine (100 mg/mL) and xylazine (20 mg/mL) administered
intraperitoneally (115mg/kg, [i.p.]), and subsequently placed on a stereotaxic device. Stereotaxic
coordinates were based on the atlas published by Paxinos and Watson (2005). Two stainless-steel
guide cannulae (22 gauge, Plastics One, Roanoke, VA, USA) were implanted bilaterally into the
medial prefrontal cortex (mPFC) or the ventral tegmental area (VTA) using the following
stereotaxic coordinates: bilateral mPFC (15° angle): anteroposterior (+2.9 mm from bregma),
lateral (-1.9 mm from bregma), and ventral (-3.0 mm from dural surface). Bilateral VTA
placements (10° angle): anteroposterior (-5.0 mm from bregma), lateral (-2.3 mm from bregma),
and ventral (-8.0 mm from dural surface). Jeweler’s screws and dental acrylic were used to
secure the cannulae. The animals had at least 7 days to recover from the surgery, and wet food
was placed to the bottom of housing cages to speed up the weight during the first 3 post surgery
days.
2.2 Drug administration
Stainless-steel guide cannulae (22 gauge) were implanted bilaterally into the mPFC or the
VTA, and drugs were infused through 28-gauge microinfusion injectors (Plastics One), which
were cut 1.0 mm longer than the guide cannulae. The 1.0 µL microsyringes (Hamilton Co., Reno,
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NV, USA) were connected to the injector by a polyethylene tube. All microinfusions were
performed at a constant rate of 1.0 µL/min (0.5 µL/hemisphere), injectors remained in place for
an additional 1 min to allow diffusion. All drugs were dissolved in physiological saline (pH 7.4).
The ERK inhibitor U0126 was dissolved in 50% dimethyl sulfoxide. Full D1R agonist SKF
81297 (10 or 100 ng/0.5uL [Tocris, United Kingdomng]), ERK1/2 inhibitor U0126 (1.0
µg/0.5uL [Tocris]), and filtered saline vehicle were infused immediately before the fear memory
test phase. The selective D4R agonist PD 168077 (5 or 50 ng/0.5µL [Tocris]), CaMKII inhibitor
autocamtide-2-related inhibitory peptide (AIP, 500 ng/0.5µL [Tocris]), and filtered saline vehicle
were infused immediately before the fear conditioning phase. Morphine (0.05 mg/kg, morphine
hydrochloride, [MacFarlane Smith, Edinburgh, Scotland]) and saline vehicle were injected (i.p.)
immediately before morphine and saline conditioning, respectively. In the VTA experiments,
bilateral intra-VTA microinjections of morphine (250 ng/0.5µL) were infused immediately
before morphine conditioning. Filtered saline was infused into the VTA immediately before
saline conditioning.
2.3 Olfactory fear conditioning
Olfactory fear conditioning was used to test the ability of the animals to recall a fear
memory formed by pairing an olfactory cue with foot shocks. Based on experimental purposes,
either subthreshold (0.4 mA) or supra-threshold (0.8 mA) foot shocks were delivered to test
whether a certain drug treatment could potentiate or block the associative fear memory. Previous
studies have reported that subthreshold (0.4 mA) foot shocks fail to elicit conditioned freezing
behaviour, and that supra-threshold foot shocks produce robust fear responses (Lauzon et al.,
2009). On day 1 (habituation phase), the animals were transported from the housing room to a
sound-attenuated room, and were habituated to the new environment for 30 min. The animals
were then removed from their cages and placed into one of two well-ventilated, identical size (30
inch × 30 inch) plexiglass conditioning chambers. Each chamber had a distinct background:
chamber A had white background with black stripes; chamber B had a white background with
black dots. One of the chambers was equipped with a metallic grid-shock floor that could be
removed during the test phase. The other chamber had a smooth plexiglass floor. The rats were
habituated to each environment for 30 min and were returned to their home cages for 5 min
between switching environments. On day 2 (conditioning phase), conditioning occurred in one of
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the two distinct environments, and counter-balanced within groups. The resources of the
olfactory cues were the almond or peppermint extract oil, which was contained in two separated
sealed vials and each vial was connected by the in-flow and the out-flow polyethylene tubes. The
animals were placed in the previously assigned shock environment and allowed to explore for 1
min. The olfactory cue (either peppermint or almond [counter-balanced within groups]) was then
administered for 19 s, followed by a foot shock (1 s), either 0.4 mA or 0.8 mA. The procedure
was repeated 5 times at 4-min intervals (animals were remained in the conditioning chamber).
The animals were then removed from the conditioning chamber 100 s after the final foot shock
and returned to the home cages. On day 3 (test phase), subjects were tested in the previously
assigned test environment (where they did not previously receive foot shock). Before presenting
the olfactory cue, animals were allowed to explore the environment for 1 min, and baseline level
of activity was observed. Odor cues were then presented for 5 min and the length of freeze time
was recorded using ANY-maze software (Stoelting Co, Wood Dale, IL, USA). The data were
analyzed as percentage of freeze (time spent freezing [s] divided by 300 s), represented as
freezing % in the graphs. Freezing was defined as a complete lack of movement other than
respiratory-related movement.
2.4 Conditioned place preference
Pavlovian conditioned place preference (CPP) was used to train the animals to form
rewarding memory related to morphine’s rewarding effects by pairing morphine injection with a
specific environment. All rats were conditioned using an unbiased, fully counter-balanced CPP
procedure as described previously (Laviolette, Nader & van der Kooy 2002). Conditioning
occurred in two distinct environments (both 15 inch × 15 inch) differing in colour, texture, and
scent. One environment was white, with a wire mesh floor and covered with wood chips. The
other environment was black with a smooth plexiglass floor, wiped with 2% acetic acid solution
before each conditioning session and test. Rats display no baseline preference for either
environment (Laviolette and van der Kooy, 2003). Treatments received (saline or morphine) in
each of the two environments were counter-balanced within the group. For example, 4 animals
received morphine injection paired with the white box environment; the other 4 animals received
morphine injection paired with the black box. Before olfactory conditioning habituation, the
animals were placed in the gray plexiglass boxes for a 30-min habituation period to minimize
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stress during future conditioning. Morphine conditioning took place immediately after the fear
recall phase in order to temporally probe how fear memory recall may or may not influence
morphine reward sensitivity. Subjects received i.p. injections of morphine (0.05 mg/kg) or
bilateral intra-VTA morphine microinfusions of morphine (250ng/0.5µL). Previous reports have
shown that these morphine treatments are sub-reward threshold and do not normally produce a
rewarding CPP effect (Lintas et al., 2012). Immediately after the injections, the rats were placed
in the previously assigned morphine environment for 30 min. Twenty-four hours later, they
received saline vehicle i.p. injections or intra-VTA saline vehicle microinfusions, followed by 30
min conditioning in another environment. The animals received one drug-environment and one
saline-environment conditioning session. At the drug-free test, the rats were placed in a grey
narrow zone that separated the two environments, and time spent in each environment over a 10min period was recorded using two stopwatches. To be scored, the animals had to have their
front paws and heads located in one environment. Increased time spent in the drug-paired
environment indicated the expression of drug-related rewarding memory, which served as a
measure of morphine’s rewarding effects or increased motivational state for the drug. The data
were analyzed as time spent (s) in each environment. The behavioural protocol for this project is
depicted in Figure 1.
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Figure 1. Behavioural procedures flow chart.
Note: fear memory test and morphine conditioning took place in the same day; after the 5-min
fear recall phase, subjects were returned to their home cage for 5 minutes and received
morphine in their housing rooms. Whereas saline conditioning took place 24h after morphine
conditioning session.
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2.5 Western blot protocol
Western blotting was used to detect changes in phosphorylation and total levels of
ERK1/2 (pERK 1/2, tERK 1/2) and CaMKII (pCaMKII, tCaMKII). Three groups of animals
received intra-mPFC saline vehicle, the selective dopamine D4 receptor (D4R) agonist PD
168077 (50 ng/0.5 µL), or full dopamine D1 receptor (D1R) agonist SKF 81297 (100 ng/0.5 µL)
microinfusions in their housing room. Five minutes after the microinfusions, the animals were
euthanized. Brains were removed and stored on dry ice for 5 min, then transferred to the -20°C
freezer. The mPFC regions were sectioned into coronal slices (100 μm), and micropunches of the
mPFC tissue were obtained. The mPFC tissue samples were then homogenized using a Dounce
homogenizer. RIPA lysis buffer (pH 8.0) containing a protease inhibitor tablet (Mini complete
tablets, Roche, USA) and phosphatase inhibitors (phosphatase inhibitor cocktail 4 [Calbiochem,
San Diego, CA, USA]; phosphatase inhibitor cocktail 2 [Sigma-Aldrich, St Louis, MO, USA]),
was used for protein isolation. The sample was then centrifuged for 1.5 h to remove debris, then
mixed with an equal volume of 2 × Laemmli loading buffer heated to 95°C for 5 min, then stored
in at -20°C for future use.
Protein samples from the saline vehicle or treatment groups (D1R and D4R agonists) were
loaded onto 10% denaturing sodium-dodecyl sulfate (SDS) polyacrylamide gels and
electrophoresed (125 V for 75 min) using a Western blotting apparatus (Mini Protean 3, Bio-Rad,
Hercules, CA, USA) filled with Tris/glycine/SDS buffer. After electrophoresis, protein was
transferred from the gels to nitrocellulose membranes (Bio-Rad) using a Mini Trans-Blot
apparatus (Bio-Rad) filled with a tris/glycine/methanol solution covered with ice at 75 V for 75
min. The nitrocellulose membranes were then blocked in 5% non-fat skim milk (NFSM) tribuffered saline and Tween 20 (TBS-T) solution for 1 h at room temperature with rocking. The
membranes were then incubated in 5% NFSM TBS-T with the appropriate primary antibodies
(Table 1) directed against the proteins of interest overnight at 4°C on a rocker. The membranes
were then washed in TBS-T three times at room temperature (10 min each time on the rocker).
Subsequently, the membranes were incubated in the NFSM TBS-T solution containing
secondary antibody (alpha tubulin: donkey anti mouse 680RD, 1:1000 [LI-COR, Lincoln, NB,
USA]; donkey anti rabbit 800CW, 1:1000 [LI-COR]) for 1 h at room temperature on a rocker.
The membranes were then washed with TBS-T two times (10 min each time with rocking) and
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once in tri-buffered saline (TBS, 10 min with rocking). The membranes were then scanned
(Odyssey Nitrocellulose Membrane Scanner, LI-COR Bioscience). Imagine Studio Lite version
5.2 (LI-COR Bioscience) was used to separate the protein blot and alpha-tubulin images, which
were then stored as separate TIF files for densitometry measurements using Molecular Imaging
software (Kodak, Rochester, NY, USA). Data were analyzed using Excel (Microsoft Corporation,
Redmond, WA, USA).
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Table 1
Name

Source

Dilution

Species

alpha tublin

Sigma-Aldrich

1:100000

Mouse

tERK1/2

Cell Signalling

1:2000

Rabbit

1:1000

Rabbit

1:1000

Rabbit

1:1000

Rabbit

Techonology
pERK1/2

Cell Signalling
Techonology

tCaMKII

Cell Signalling
Techonology

pCaMKII

Cell Signalling
Techonology
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2.6 Histology
After the experiments were completed, the animals were injected (i.p.) with 1.0 mL
sodium pentobarbital (240mg/mL, Euthanyl, BI-MEDA Animal Health Inc, Cambridge, ON,
Canada) perfused with isotonic saline, then 10% formalin. Brains were removed and stored in
formalin (10%) for 24 h, then transferred to a 10% formalin/25% sucrose solution for at least 3
days, and stored at 4°C. The brains were then sectioned into coronal slices (40 μm) using a
cryostat, and stained using Cresyl violet, and mounted. The cannulae placements for the mPFC
and the VTA were verified under a light microscope. Animals that had cannulation sites outside
the anatomical boundaries of the PFC and VTA areas (defined by Paxinos and Watson [2005])
were excluded from data analysis.
2.7 Data analysis
All data were analyzed using one- or two-way ANOVA, or the Student’s t test, followed
by Tukey post hoc test or Student’s t test where appropriate. In the graphical representations of
the data, the vertical bars on the group means represent the standard error of the mean, asterisks
(*) indicate a level of significance of < 0.05, and double asterisks (**) indicate a level of
significance of < 0.01.
3 Results
3.1 Recall of associative fear memory increases sensitivity to morphine’s rewarding effects
To investigate the effects of fear memory expression on morphine sensitivity, 3 groups of
animals (n=8 in each group) were recruited. Two groups were conditioned to supra-threshold
fear conditioning (0.8 mA foot shock); however, 1 of these groups was not presented with cue
during the test phase. The third group was included as a control, which did not receive foot shock.
Bilateral intra-mPFC microinfusions of saline vehicle for all subjects were administered before
the test stage. Systemic injections of the subthreshold dose of morphine (0.05 mg/kg) and saline
were administered before the morphine and the saline conditioning phase, respectively. The
representative microphotograph of bilateral intra-mPFC microinjector tip placements is
illustrated in Figure 2A. A schematic representation of bilateral intra-mPFC injector tip
placements for the representative groups is presented in Figure 2B.
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Figure 2
Presentation of intra-mPFC guide cannulae placements
(A) Microphotograph of the representative bilateral intra- mPFC guide cannulae and injector
tip placement.
(B) Schematic representation of bilateral intra-mPFC injector tip placements. ○= no fear group,
⌂= fear no recall group, ●= fear recall group, □= SF81297 100ng/0.5ul, filled ⌂= Veh control
group (sub-threshold fear conditioning), ■= PD168077 50ng/0.5ul
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The results of fear conditioning recall testing revealed that groups that were conditioned
with supra-threshold fear conditioning showed increased freezing levels relative to the no shock
control group. However, relative levels of freezing were much higher in the group receiving the
cue presentation during testing (~ 70%), as opposed to the no cue presentation group (~20%;
Figure 3A). However, in the subsequent morphine CPP test phase, only rats previously receiving
the cue presentation during the fear memory recall test showed a significant morphine CPP
(Figure 3B).
In terms of fear memory recall, one-way ANOVA revealed a significant main effect of
group (no shock, fear no cue, fear with cue: F (2, 23) = 170.399, p<0.01) on freezing behaviours.
Post hoc analysis indicated that experiencing foot shock (fear no cue, fear with cue) displayed
significantly increased freezing relative to the no fear control group (p<0.01). However, rats
receiving the cue presentation during the recall testing displayed dramatically increased freezing
relative to rats that had experienced foot shock conditioning, but were not presented with the
associative cue at testing (p< 0.01). Two-way ANOVA analysis of the CPP test revealed a
significant main effect of group (no shock, fear no cue, fear with cue: F (2, 21) = 21.936; p<0.01),
environment (morphine, saline: F (1, 21) = 181.237; p<0.01), and a significant group*environment
interaction (F (2, 21) = 106.803; p<0.01). Post hoc analysis indicated that the fear with cue group
exhibited increased morphine preference compared with the corresponding saline environment
(p<0.01). Comparing only the time spent in the morphine environment, fear groups exhibited
significant preference in the morphine environment relative to the no shock and no cue groups
(p<0.01).
Thus, these findings demonstrate that the selective recall of an associative fear memory,
dramatically increases sensitivity to the rewarding effects of a normally non-rewarding
conditioning dose of morphine (0.05 mg). Neither rats receiving no shock during conditioning,
nor rats that experienced foot shock conditioning (but were not presented with a conditioned cue
to trigger the fear memory recall), showed a significant morphine CPP.
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Figure 3. Behavioural effects of supra-threshold foot shock and fear memory expression on
conditioned fear response and morphine sensitivity.
(A) In the no shock group, no demonstrable conditioned fear response was observed. Suprathreshold foot shock (0.8 mA) induced a weak fear response in the fear no cue group and a
robust and strong fear memory response in the fear with cue group.
(B) Only the fear with cue group exhibited significant morphine preference relative to salineassociated context in the conditioned place preference (CPP) test. Comparing only the time
spent in the morphine environment, the fear with cue group also spent a significantly longer time
in the morphine context compared with the other 2 groups.
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3.2 Activation mPFC D1R inhibited fear memory expression and blocked potentiated
morphine CPP
To further investigate the influence of fear memory expression on morphine sensitivity, it
was then decided to test whether inhibition of memory expression could decrease the potentiated
morphine sensitivity observed in the previous experiment. Research has shown that mPFC D1
transmission regulates memory expression (Lauzon et al., 2009); thus, the effects of D1R super
stimulation on both fear and rewarding memory recall were challenged. The experiment included
2 groups, which received different doses of the D1R agonist SKF81297 (10 ng/0.5 µL [n=8] or
100 ng/0.5 µL [n=8]) immediately before the test stage, followed by i.p. morphine injections
administered before morphine conditioning. The no shock group was included in the data
analysis and graphs for comparative purposes.
Results showed that bilateral mPFC SKF81297 infusion dose-dependently blocked the
expression of fear memory as well as decreased the potentiated morphine preference (Figure 4 A
and B). One-way ANOVA revealed a significant treatment effect (no shock, SKF81297 [10
ng/0.5 µL], SKF81297 [100 ng/0.5 µL]) on freezing behaviour: (F (2, 23) = 27.143; p<0.01). Post
hoc analysis revealed that the higher dose (100 ng/0.5 µL) of SKF81297 fully blocked fear
memory recall. The freezing percentage was not different compared with animals in the no shock
group (p>0.05); whereas the lower dose (10 ng/0.5 µL) failed to attenuate aversive memory
expression. The animals exhibited significant higher levels of freezing compared with the higherdose and no shock groups (p<0.01). Two-way ANOVA analysis of the CPP tests revealed a
significant main effect of environment (morphine, saline: F (1, 21) = 9.805; p<0.01). Post hoc tests
revealed no morphine preference in the no shock and high dose groups (p>0.05), and animals in
lower-dose group spent a significantly longer time in the morphine context compared with the
saline environment (p<0.01).
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Figure 4. Behavioural effects of bilateral medial prefrontal cortex (mPFC) dopamine D1
receptor (D1R) activation on fear memory expression and morphine induced place preference.
(A) Animals in the no shock group and those receiving bilateral mPFC infusion of the higher
dose of D1R agonist (SKF81297 [100 ng/0.5 µL]) exhibited no conditioned fear response.
Treatment with the lower dose of SKF81297 (10 ng/0.5 µL) failed to block the expression of
aversive fear memory because subjects exhibited a significantly higher percentage of freezing.
(B) Animals in the no shock and higher-dose D1R agonist group exhibited no significant
morphine preference. Animals receiving the lower dose of SKF81297 (10 ng/0.5 µL) spent
significantly more time in the morphine-paired environment.
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3.3 Inhibition of cAMP reversed the effects of mPFC D1R stimulation on aversive memory
expression but had no impact on rewarding memory expression
To further examine the role of mPFC D1 transmission on memory expression and its
associated molecular pathways, a reversal experiment was performed with cAMP inhibition,
given that previous research has demonstrated mPFC D1 transmission is associated with cAMP
activity (Lauzon et al., 2013). Animals in two groups received bilateral mPFC co-administration
of the effective dose of SKF81297 (100 ng/0.5 µL) and different doses of the cAMP inhibitor
Rp-cAMP (100 ng/0.5 µL; 500 ng/0.5 µL [n=8 in each group]), before the fear test stage. The
following protocols were identical to those previously described. The SKF81297 (100 ng/0.5 µL)
group from the previous experiment was included in the data analysis and figures for comparison.
Results indicated that bilateral mPFC Rp-cAMP infusion dose dependently reversed the
effect on D1R activation on fear memory expression, while cAMP inhibition had no effect on
regulation of morphine sensitivity and rewarding memory expression (Figure 5 A and B). Oneway ANOVA revealed a significant main effect of treatment (SKF81927 [100 ng/0.5µL] alone,
co-administration with Rp-cAMP [100 ng/0.5 µL and 500 ng/0.5 µL] on freezing response (F (2,
23)

= 11.199; p<0.01). Post hoc analysis indicated that, compared with SKF81927 infusion alone,

the lower dose of Rp-cAMP (100 ng) failed to reverse its effect on fear memory blocking
(p>0.05); animals in this group spent the same amount of time freezing. However, the higher
dose of Rp-cAMP (500 ng) fully reversed the effect of D1R activation, and the freezing
percentage was significantly higher compared with agonist alone and co-administration with
lower-dose Rp-cAMP groups. Two-way ANOVA analysis of the CPP tests revealed a significant
main effect of environment (morphine, saline: F (1, 21) =23.929; p<0.01) and
treatment*environment interaction (F (2, 21) = 3.757; p<0.05). Post hoc analysis indicated that
both co-administration groups exhibited significant increased morphine preference compared
with their corresponding saline environments (p<0.01), which reflects that, although cAMP
mediated fear memory expression, it is not the lynchpin mechanism for morphine sensitivity and
rewarding memory expression.
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Figure 5. Behavioural effects of bilateral medial prefrontal cortex (mPFC) cAMP inhibition on
dopamine D1 receptor (D1R) stimulation in the regulation fear memory expression and morphine
sensitivity.
(A) Rp-cAMP dose- dependently reversed the effect of D1R activation on fear memory expression.
Animals receiving SKF81297 alone, and those receiving co-administration of the lower dose of
Rp-cAMP (100 ng/0.5µL) did not exhibit significant fear response. The group receiving coadministration of the higher dose of Rp-cAMP (500 ng/0.5µL) exhibited significant increases in
freezing percentage.
(B) cAMP inhibition failed to block potentiated morphine conditioned place preference (CPP).
Both groups received co-administration of SKF81297 and Rp-cAMP spent significantly more
time in the morphine environment compared with the saline-paired context. Only SKF81297
infusion alone blocked morphine CPP.
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3.4 mPFC D4 transmission bi-directionally regulated the acquisition of fear memory and
sensitivity to morphine’s rewarding effects
Previous research has reported that D4 transmission mediates the acquisition of memory,
and its effects are bidirectional and depend on baseline neuronal activities (Gu & Yan, 2004;
Lauzon et al., 2013). To further investigate the effect of aversive memory recall on morphine
sensitivity regulation, the effects of mPFC D4 transmission on the modulation of associative fear
and rewarding memory were then examined. First, the effect D4 transmission in lower baseline
neuronal activity was examined; thus, subthreshold fear conditioning was used. Lauzon et al
(2009) demonstrated that receiving subthreshold foot shocks (0.4 mA) did not induce significant
fear response in rodents. In this experiment, the effect of the D4R agonist PD168077 on aversive
and the rewarding memory acquisition was tested. Three groups were used: saline (Veh [n=9]);
PD169077 (5 ng/0.5 µL [n=6]); and PD169077 (50 ng/0.5 µL [n=9]). Intra-mPFC infusions were
administered immediately before the fear conditioning stage. Twenty-four hours later, they were
tested for fear memory recall and followed by morphine conditioning. Saline conditioning
occurred 24 h after morphine conditioning, as previously described.
Results indicated that subthreshold foot shock failed to elicit a strong fear response in
both the Veh and lower-dose agonist (5 ng/0.5 µL) groups; however, treating with higher doses
(50 ng/0.5 µL) before the acquisition stage potentiated the salience of a subthreshold fear
stimulus, animals in this group demonstrated an increased level of fear behaviours during the test
(Figure 6 A). This group also exhibited potentiated morphine preference in the CPP; however,
the Veh and lower-dose groups did not demonstrate increased morphine sensitivity (Figure 6 B).
One-way ANOVA test for fear expression revealed a significant main effect of treatment
(Veh, PD169077 [5 ng/0.5 µL], and PD169077 [50 ng/0.5 µL] on freezing percentage (F (2, 23) =
29.817; p<0.01). Post hoc analysis indicated that the group receiving 50 ng/0.5 µL of the D4R
agonist exhibited significantly increased freezing percentage compared with the Veh and lowerdose groups (p<0.01). The freezing percentage was not different between the Veh and lowerdose group (p>0.05). Two-way ANOVA analysis of the CPP test indicated significant main
effects of treatment (Veh, PD169077 [5 ng/0.5 µL], and PD169077 [50 ng/0.5 µL]: F (2, 21) =
5.764; p<0.05), environment (morphine, saline: F (1, 21) = 18.799; p<0.01), and
treatment*environment interaction (F (2, 21) = 5.788; p<0.05). Post hoc tests revealed that time
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spent in the morphine environment in the PD168077 (50 ng/0.5 µL) group was significantly
longer compared with saline (p<0.01), and compared with the time spent by the Veh group in the
morphine environment (p<0.05) and the lower-dose groups (p<0.01). The other two groups
failed to exhibit potentiated morphine sensitivity in the CPP test (p>0.05).
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Figure 6. Behavioural effects of bilateral medial prefrontal cortex dopamine D4 receptor (mPFC
D4R) activation on fear response and morphine conditioned place preference (CPP) in
subthreshold fear conditionings.
(A) In subthreshold fear conditioning, both the vehicle (Veh) and lower-dose PD168077 (5
ng/0.5 µL) treatments failed to induce strong associative fear memory. The higher dose of
PD168077 (50 ng/0.5 µL) potentiated the salience of subthreshold fear stimuli; hence, animals
in this group exhibited significant increased freezing percentage.
(B) Bilateral mPFC D4R activation in subthreshold fear conditioning subsequently increased
morphine preference in the higher-dose agonist group.
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Next, we examined the effects mPFC D4R activation on memory acquisition of in the
supra-threshold fear conditioning, which assembles the higher baseline neuronal activity. In this
experiment, the Veh and the treatment groups (n=8 in each group) received saline vehicle and the
effective dose of PD168077 (50ng/0.5 µL) before receiving supra-threshold foot shocks (0.8
mA). The following fear memory test and CPP conditioning tests procedures were identical as
previously described.
In supra-threshold fear conditioning, bilateral mPFC D4R activation attenuated the
acquisition of salient fear stimuli because the treatment group did not exhibit elevated freezing
percentage compared with the Veh. In the CPP test, both groups exhibited significant morphine
preference (Figure 7 A and B). Student’s t test for fear conditioning indicated that the Veh group
exhibited significantly higher freezing percentage compared with the treatment group (p<0.01).
Two-way ANOVA of CPP test results revealed a significant main effect of environment
(morphine, saline: F (1, 14) = 21.385; p<0.05). Post hoc indicated both the Veh and treatment
groups spent a significantly longer time in the morphine-paired context.
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Figure 7. Behavioural effects of bilateral medial prefrontal cortex dopamine D4 receptor (mPFC
D4R) activation on the acquisition of supra-threshold fear stimulus and morphine sensitivity.
(A) In supra-threshold fear conditioning, bilateral mPFC D4R activation attenuated the learning
of an emotional salient fear stimulus; animals receiving PD168077 (50 ng/0.5 µL) demonstrated
a significantly lower freezing percentage compared with the vehicle (Veh) group.
(B) Morphine conditioned place preference (CPP) tests revealed that both the Veh and treatment
groups spent significantly more time in the morphine-paired environment.
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3.5 Bilateral mPFC D4R and D1R co-activation control the acquisition and expression of
aversive and rewarding memory
After investigating the role of D4 and D1 transmission, an attempt was made to link their
functions. Using subthreshold fear conditioning, it was tested whether D1R activation at the
recall stage could block the expression of strong fear memory potentiated by D4R stimulation
during the conditioning stage, and if co-activation of both receptor systems could affect the
animals’ sensitivity to morphine. Two groups of animals both received the effective dose of D4R
agonist (PD168077 [100 ng/0.5 µL,]) before conditioning. The Veh group (n=8) received saline,
and the treatment group (n=7) received the effective dose of D1R agonist SKF81297 (100 ng/0.5
µL) before the fear test stage. CPP procedures were identical to those described previously.
Results revealed that bilateral mPFC D4R activation at the conditioning phase potentiated
the salience of subthreshold fear stimuli in the Veh group; mPFC D1R activation at the recall
phase was able to block the expression of potentiated fear memory. The CPP tests indicated that
D1R agonist treatment also blocked the expression of morphine preference (Figure 8 A and B).
Student’s t test revealed a significant decrease in freezing percentage in the treatment group
compared with the Veh group (p<0.05). Two-way ANOVA of the CPP test revealed no
significant effect. The Student’s t test was used to analyze differences in the time spent in the
morphine- and the saline-paired environments. In the Veh group, the animals spent significantly
more time in the morphine-associated environment.
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Figure 8. Behavioural effects of bilateral medial prefrontal cortex dopamine D4 receptor (mPFC
D4R) and dopamine D1 receptor (D1R) co-activation in subthreshold fear conditioning and
morphine preference test.
(A) Activation of mPFC D4R facilitated the acquisition of emotionally non-salient fear stimuli
because the vehicle (Veh) group exhibited higher freezing percentages. Animals receiving the
D1R agonist SKF81297 (100 ng/0.5 µL) before the test phase blocked the expression of
potentiated fear memory.
(B) The SKF81297 (100 ng/0.5 µL) group spent an equal length of time in the morphine- and
saline-paired environments; the Veh group exhibited a strong morphine preference.
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3.6 mPFC D4R and D1R stimulation increased phosphorylation of CaMKII and ERK1/2
There is substantial literature suggesting that D4 and D1 transmissions are closely linked
to the activities of CaMKII and ERK1/2. To further investigate the molecular pathways
associated with D4 with D1 transmission, western blot analysis were performed to examine
phosphorylation levels of CaMKII- and ERK1/2 following D4R and D1R stimulation. Three
groups of animals received bilateral intra-mPFC infusion of saline (Veh [n=6]), SKF81297 (100
ng/0.5 µL [D1R activation] [n=6]), and PD168077 (50 ng/0.5 µL [D4R activation] [n=5]),
followed by brain extraction as described in the previous section.
Results indicated that D1R stimulation significantly increased phosphorylation levels of
both ERK 1 and 2. Total ERK1 level was not affected by D1R stimulation; however, total ERK 2
(tERK 2) was increased by SKF81297 infusion. Both pERK1/ tERK1 and pER2/ tERK2 were
increased following D1R stimulation (Figure 9, Figure 10).
One-way ANOVA revealed a significant main effect of treatment (saline Veh; SKF81297
[100 ng/0.5 µL]; PD168077 [50 ng/0.5 µL]) on pERK1 levels: (F (2, 17) = 4.10136; p<0.05) and
pERK2: (F (2, 17) = 5.44336; p<0.05). Post hoc tests indicated that, compared with the Veh group
and D4R activation, D1R stimulation led to a significant increase in pERK1 levels (p<0.05); the
same trend was also observed in pERK2 post hoc analysis (p<0.01 vs Veh; p<0.05 vs PD168077
[50 ng/0.5 µL]).
One-way ANOVA revealed no significant change in tERK1 levels; however, a significant
main effect of treatment on tERK2 level (saline Veh; SKF81297 [100 ng/0.5 µL]; PD168077 [50
ng/0.5 µL]: F (2, 17) = 6.00827; p<0.05). Post hoc tests indicated that, compared with the Veh
group, both D1R and D4R activation led to a significant reduction in tERK 2 levels (p<0.05 vs
SKF81297; p<0.01 vs PD168077).
The ratios of pERK1 to tERK1, and pERK2 to tERK2, were also analyzed. One-way
ANOVA revealed a significant main effect of treatment (saline Veh; SKF81297 [100 ng/0.5 µL];
PD168077 [50 ng/0.5 µL]) on pERK1/tERK1: (F (2, 17) = 3.645; p<0.05) and pER2/tERK2 (F (2, 17)
= 5.271; p<0.05). Post hoc analysis indicated that both pERK1/tERK1 and pERK2/tERK2 ratios
were significantly elevated in the SKF81297 (100 ng/0.5 µL) group compared with the Veh
group.
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Figure 9. Western blot analysis of ERK1 following bilateral microinfusions of saline, dopamine
D4 receptor (D4R) agonist PD168077 (50 ng/0.5 µL)) and D1R agonist SKF81297 (100 ng/0.5
µL) in to the medial prefrontal cortex (mPFC).
(A) Representative western blot for tERK1and pERK1 expression.
(B) The ratio of pERK1/tERK1 was increased in the group receiving SFK81297.
(C) Densitometry analysis revealed significant increase of pERK1 expression following D1R
activation.
(D) Densitometry analysis revealed no significant change in tERK1expression following D1R
activation.
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Figure 10 Western blot analysis of ERK2 following bilateral microinfusions of saline, dopamine
D4 receptor (D4R) agonist PD168077 (50 ng/0.5 µL)) and D1R agonist SKF81297 (100 ng/0.5
µL) in to the medial prefrontal cortex (mPFC).
(A) Representative western blot for tERK2 and pERK2 expressions.
(B) The ratio of pERK2/tERK2 was increased in group received SFK81297.
(C) Densitometry analysis revealed significant increase of pERK2 expression following D1R
activation.
(D) Densitometry analysis revealed a significant reduction in tERK2 expression following D1R
and D4R activation compared to the Veh group.
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Following PFC D4R stimulation, pCaMKII- was significantly increased without
changing the tCamKII- expression level (Figure 11). One-way ANOVA revealed a significant
main effect of treatment (saline vehicle, SKF81297 [100ng/0.5 µL], PD168077 [50ng/0.5 µL])
on pCaMKII- expression (F (2, 14) = 6.56259, p<0.05). Post hoc tests indicated that compare to
Veh group, D4R activation led to significant increase of pCaMKII- level (p<0.01). One-way
ANOVA revealed no significant change in tCaMKII- level and pCaMKII-/ tCaMKII- ratio.
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Figure 11 Western blot analysis of CaMKII- following bilateral microinfusions of saline,
dopamine D4 receptor (D4R) agonist PD168077 (50 ng/0.5 µL)) and D1R agonist SKF81297
(100 ng/0.5 µL) in to the medial prefrontal cortex (mPFC).
(A) Representative western blot for tCaMKII- and pCaMKII- expression.
(B) The ratio of pCaMKII-/tCaMKII- was not changed in all treatment groups.
(C) Densitometry analysis revealed a significant increase of pCaMKII- expression following
D4R activation.
(D) Densitometry analysis revealed no significant change in tCaMKII- expression following
D4R activation.

56

57

3.7 ERK1/2 inhibition reversed the effect of mPFC D1R stimulation on fear memory
expression and potentiation of morphine sensitivity
It was demonstrated that mPFC D1R activation increased phosphorylation levels of
ERK1/2, as well as attenuating both fear and rewarding memory expression at the behavioural
level. It was then decided to test whether inhibition of ERK activity could affect the ability of D1
to regulate fear and rewarding memory. In this experiment, two groups of rats received suprathreshold fear conditioning: one group received the ERK inhibitor U0126 (1000 ng/0.5 µL); the
other group received co-administration of U0126 (1000 ng/0.5 µL) and SKF81297 (100 ng/0.5
µL). Bilateral intra-mPFC infusions were performed immediately before the fear recall phase.
Two other groups, fear with cue and SKF81297 (100 ng/0.5 µL), were included in data analysis
and figures for the purpose of comparison, all groups consisted of 8 animals.
Results demonstrated that bilateral mPFC D1R activation with SKF81297 alone inhibited
the aversive and morphine-related rewarding memory expression compared with the fear with
cue group. U0126 alone had no effect on fear response and rewarding memory expression
compared with the fear with cue group. Co-administration of ERK inhibitor and D1R agonist
reversed the effect of D1 activation on aversive and rewarding memory blocking (Figure 12 A &
B).
One-way ANOVA analysis of fear tests revealed a significant treatment effect (fear with
cue; SKF81297 [100 ng/0.5 µL]; U0126 [1000 ng/0.5 µL]; and U0126 [1000 ng/0.5 µL] +
SKF81297 [100 ng/0.5 µL]) on freezing percentage (F (3, 31) = 55.704; p<0.05). Post hoc tests
indicated that U0126 infusion alone had no effect on freezing behaviour compared with the fear
with cue group (p>0.05). Animals in this group exhibited a significantly strong fear response
after receiving 0.8 mA foot shocks compared with the SKF81297 infusion alone (p<0.01) and
co-administration groups (p<0.01). Co-administration with SKF81297 fully reversed the effect
of D1R activation on memory expression: the animals exhibited significantly elevated levels of
fear response compared with SKF81297 infusion alone (p<0.01), and no change in freezing
percentage compared with the fear recall control group (p>0.05). Two-way ANOVA analysis of
CPP tests revealed significant main effects of treatment (fear with cue, SKF81297 [100 ng/0.5
µL], U0126 [1000 ng/0.5µL], U0126 [1000 ng/0.5 µL] + SKF81297 [100 ng/0.5 µL]: F (3, 30) =
6.311; p<0.01), environment (morphine, saline: F (1, 30) = 103.499; p<0.01), and
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treatment*interaction (F (3, 30) = 34.985; p<0.01). Post hoc analysis indicated that U0126 infusion
alone had no effect on morphine preference compared with the saline environment (p>0.05). Coadministration with SKF81297 reversed the effect of D1R activation on morphine CPP blockade.
Animals in this group spent significantly more time in the morphine-paired context (p<0.01).
Compared with the morphine environment time-spent alone, the fear with cue group spent
significantly more time in the morphine environment compared with the other 3 groups (p<0.01).
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Figure 12. Behavioural effects of bilateral medial prefrontal cortex (mPFC) ERK1/2 inhibition
on dopamine D1 receptor (D1R) activation in supra-threshold fear conditionings and morphine
conditioned place preference (CPP).
(A) In supra-threshold fear conditioning, the fear with cue group, U0126 treatment alone, and
co-administration group, exhibited a strong fear response. SKF81297 infusion alone blocked
fear memory recall, and the effect was reversed by co-infusion with U0126 (1000 ng/0.5 µL)
because the co-administration group demonstrated significant higher freezing percentage
compared with SKF81297 infusion alone.
(B) CPP tests revealed significant morphine preference in fear with cue and co-infusion groups.
Animals in the fear with cue group spent more time in the morphine-paired environment
compared with the other 3 groups.
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3. 8 CaMKII inhibition reversed the effects of mPFC D4R activation on fear memory
acquisition and decreased potentiated morphine sensitivity
Western blot results indicated increased levels of CaMKII- phosphorylation following
D4R activation. It was then examined whether inhibition of CaMKII activity in the mPFC could
reverse the effect of D4R activation on fear and rewarding memory regulation. In this experiment,
two groups of animals received subthreshold fear conditioning: the first group (n=8) received the
CaMKII inhibitor AIP (500 ng/0.5 µL); the other group (n=8) received co-administration of AIP
(500 ng/0.5 µL) and PD168077 (50 ng/0.5 µL). Bilateral mPFC infusions were performed
immediately before the conditioning phase. The two other groups from the subthreshold fear
conditioning experiment (Veh control and PD168077 [50 ng/0.5 µL]) were included in data
analysis for comparative purposes.
The fear conditioning results indicated that PD168077 infusion alone potentiated the
acquisition of subthreshold fear stimuli and sensitivity to morphine’s rewarding effects, AIP
infusion alone had no effect on fear acquisition and morphine preference compared with the Veh
group. Co-infusion of AIP and PD168077 reversed the effect of mPFC D4R stimulation on the
learning of non-saline fear stimuli because animals in this group failed to exhibit a strong fear
response in comparison. This treatment also blocked potentiated morphine CPP (Figure 13 A
and B).
One-way ANOVA test for fear recall indicated a significant main effect of treatment
(Veh; PD168077 [50 ng/0.5 µL]; AIP [500 ng/0.5 µL]; and AIP [500 ng/0.5 µL] + PD168077
[50 ng/0.5 µL]) on freezing behaviour (F (3, 33) = 21.417; p<0.01). Post hoc analysis revealed that,
compared with the Veh group, only PD168077 infusion alone elicited a significant increase in
freezing percentage (p<0.01). Moreover, the amount of elevated fear response was significantly
higher compared with the AIP infusion alone and co-infusion groups (p<0.05). Two-way
ANOVA analysis of CPP results revealed a significant main effect of environment (morphine,
saline: F (1, 30) = 22.425; p<0.01) and significant treatment*environment interaction (F (3, 30) =
3.607; p<0.05). Post hoc tests revealed that PD168077 infusion alone significantly increased
morphine preference compared with the saline environment (p<0.05). The time spent in the
morphine environment in this group was also significantly longer than the other 3 groups
(p<0.05).
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Figure 13 Behavioural effects of bilateral medial prefrontal cortex (mPFC) CaMKII inhibition
on dopamine D4 receptor (D4R) activation in subthreshold fear conditionings and morphine
conditioned place preference (CPP).
(A) In subthreshold fear conditioning, the Veh group, the group received AIP alone and the coadministration group failed to show strong fear response; PD168077 (50ng/0.5 µL) infusion
alone potentiated the acquisition of subthreshold fear stimuli.
(B) CPP tests revealed significant morphine preference only in groups received PD168077 alone,
animals in this group spent more time in the morphine-paired environment compared with the
other 3 groups.
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3.9 VTA mediates potentiated morphine sensitivity in a post-traumatic stress disorder rat
model
Research in past decades has established the role of the VTA in regulating the rewarding
effects of addictive drugs such as morphine and heroin. An attempt was made to investigate
whether the VTA is also the brain region that regulates potentiated morphine sensitivity after the
animals recall an associative fear memory. Four groups of animals were recruited, all of which
underwent quartet cannulations: bilateral in the mPFC; and bilateral in the VTA. In these two
experiments, bilateral intra-VTA morphine infusions (250 ng/0.5 µL) were performed before
morphine conditioning, instead of i.p. administration of morphine; bilateral intra-VTA saline
infusions were given before the saline conditioning sessions.
Two groups were included in supra-threshold fear conditioning: the Veh control group
(n=7) received saline; and the treatment group (n=6) received the D1R agonist SKF81297 (100
ng/0.5 µL). Bilateral intra-mPFC infusions were administered before the fear test phase. The
remaining two groups were included in subthreshold fear conditioning. Intra-mPFC infusions
were administered before the fear conditioning stage, in which the Veh control group (n=7)
received saline and the treatment group (n=8) received the D4R agonist PD 168077 (50 ng/0.5
µL). A representative microphotograph of bilateral intra-VTA microinjector tip placements is
presented in Figure 14 A. A schematic representation of bilateral intra-VTA injector tip
placements is shown in Figure 14 B.
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Figure 14 Presentation of intra-VTA guide cannulae placements
(A) Microphotograph of a representative bilateral intra- VTA guide cannulae and injector tip
placement.
(B) Schematic representation of bilateral intra-VTA injector tip placements. ○= Veh control
group (sub-threshold fear conditioning), ●= PD168077 50ng/0.5ul, □= Veh control group
(supra-threshold fear conditioning), ■= SF81297 100ng/0.5ul
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Figure 14
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In supra-threshold fear conditioning, bilateral infusions of intra-mPFC SKF81297
decreased expression of a strong associative fear memory compared with the Veh group.
Bilateral intra-VTA infusions of morphine following aversive memory recall potentiated
morphine preference only in the Veh group but not the treatment group (Figure 15 A and B). In
subthreshold fear conditioning, bilateral infusions of mPFC PD168977 potentiated the salience
of subthreshold fear stimuli; the animals exhibited heightened fear response compared with the
Veh group. Intra-VTA morphine infusions potentiated the rewarding effects of subthresholddose morphine, animals in the treatment group exhibited a strong morphine preference in the
CPP test (Figure 15 C and D).
Student’s t test results for supra-threshold fear recall demonstrated a significantly
decreased freezing percentage in the treatment group (p<0.01). Two-way ANOVA revealed a
significant main effect of environment (morphine, saline: F (1, 11) = 12.157; p<0.01). Post hoc
tests indicated that the Veh group spent significantly more time in the morphine-paired
environment than the saline environment (p<0.01). Student’s t test results for subthreshold fear
recall revealed significant increases in freezing percentage in the treatment group (p<0.01). Twoway ANOVA analysis of the CPP test indicated a significant main effect of environment
(morphine, saline: F (1, 13) = 20.612; p<0.01) and a significant treatment (saline: PD168077 [50
ng/0.5 µL]) * environment interaction (F (1, 13) = 8.542; p<0.05). Post hoc analysis revealed that
in the treatment group, the animals spent significantly more time in the morphine-paired
environment compared with the saline environment (p<0.01), as well as compared with time
spent by the Veh group in the morphine environment (p<0.01).
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Figure 15 Behavioural effects of bilateral intra-VTA morphine infusions follow medial
prefrontal cortex (mPFC) dopamine D1 receptor (D1R) or dopamine D4 receptor (D4R)
activation in the supra-threshold or the subthreshold fear conditioning.
(A) Bilateral mPFC infusions of D1R agonist, SKF81297 (100ng/0.5 µL), fully blocked the fear
memory recall; compared to the Veh group, the treatment group displayed significant less
freezing percentage.
(B) Bilateral intra-VTA morphine infusions followed fear memory recall potentiated morphine
sensitivity and preference only in the Veh group.
(C) Bilateral mPFC infusions of D4R agonist, PD168077 (50ng/0.5 µL), potentiated the
acquisition of subthreshold fear stimuli; compared to the Veh group, the treatment group
displayed significant higher freezing percentage.
(D) Bilateral intra-VTA morphine infusions followed fear memory recall potentiated morphine
sensitivity and preference in the treatment group.
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4 Discussion
Disturbances in mesocorticolimbic dopamine (DA) transmission are well-established
features of comorbid neuropsychiatric disorders involving pathological memory processing, such
as post-traumatic stress disorder (PTSD) and opioid addiction. Transmission through PFC DA D4
receptors (D4R) has been shown to potentiate the emotional salience of normally non-salient
emotional memories whereas transmission through PFC DA D1 receptors (D1R) has been
demonstrated to selectively block the recall of either reward or aversion-related associative
memories. In the present study, using a combination of fear conditioning and opiate reward
place conditioning in rats, we examined the role of PFC D4R/D1R signaling during the
processing of fear-related memory acquisition and recall as well as subsequent sensitivity to
opiate reward memory formation. We report that PFC D4R activation potentiates the salience of
normally subthreshold fear conditioning memory cues and simultaneously strongly potentiates
the rewarding properties of sub-reward threshold systemic or intra-ventral tegmental area (VTA)
morphine conditioning cues. In contrast, selectively blocking the recall of salient fear memories
with intra-PFC D1R activation, blocks the ability of fear memory recall to potentiate systemic or
intra-VTA morphine reward salience. These effects are dependent upon dissociable PFC
phosphorylation activation states of either calcium-calmodulin-kinase II (CaMKII-) or
extracellular-signal-related-kinase 1/2 (ERK 1/2), following intra-PFC D4R or D1R activation,
respectively. Together, these findings reveal critical new insights into how aberrant PFC
DAergic transmission and downstream molecular signaling pathways may modulate fear-related
emotional memory encoding and recall, and how these effects may increase opioid addiction
liability during emotional memory recall in traumatic memory disorders such as PTSD.
In summary, the present thesis links the processing of associative fear and rewarding
memory to a common, DA D1 and D4 transmission directly in the PFC; and demonstrates
dynamic interactions between cue-triggered fear memory recall and the potentiation of morphine
reward salience. In addition, our results revealed novel roles for D1R and D4R-linked signaling
through the cAMP, ERK 1/2 and CaMKII pathways, in the context of PFC DAergic regulation of
fear and morphine-related reward memory processing.
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4.1 Fear memory recall strongly regulates opiate reward salience
Using olfactory fear conditioning combined with morphine CPP, a novel connection
between fear memory recall and the perception of morphine rewarding salience was identified.
Specifically, while subthreshold conditioning doses of morphine did not induce morphine
preference in rats that were not exposed to associative, fear-related recall cues, the cue-induced
recall of a previously established associative fear memory induced a robust morphine reward
CPP. It is known that various types of stressors, such as social defeat, food restriction, predator
threat are capable of reinstating drug taking behaviours in rats (Edward et al., 2013; Do Couto et
al., 2006; Shalev 2012). Here, we demonstrated that fear memory recall alone is sufficient to
potentiate the reward salience of normally non-rewarding conditioning doses of morphine.
Chronic or acute stress leads to alterations in brain function especially in the mPFC
region, including abnormal signal transduction in the mPFC-amygdala pathway (Edwards et al.,
2013; Knox et al., 2010; Milad & Quirk 2002). Furthermore, cue-triggered fear memory recall
also alters activities in various brain regions, such as the PFC, amygdala and hippocampus
(Milad et al., 2007). Nevertheless, the PFC is a vital brain region regulating inhibitory control as
well as executive and cognitive functions and is influenced by DA transmission in the
mesocorticolimbic DA pathway.
In the present thesis, I found that increasing mPFC D1 transmission inhibited fear
memory recall as well as blocked the potentiation of morphine CPP reward memories.
Functionally, mPFC D1R- mediated transmission increases the excitability of inhibitory GABA
interneurons, which in turn may decrease the excitatory tone of PFC pyramidal neurons,
increasing feedforward inhibition, which blunts the recall of the associative emotional memories
(Lauzon et al., 2013; Seamans, Gorelova, Durstewitz & Yang, 2001). Similar results have been
reported previously wherein stimulation of mPFC D1R impairs the recall of aversive fear
memories (Lauzon et al., 2009). Thus, mPFC D1 receptors play a vital role in emotional memory
recall. While there is currently direct clinical evidence for PFC D1R abnormalities in PTSD
clinical populations, one possibility is that chronic PTSD leads to long-term abnormalities in
cortical D1R activation states (or downstream signaling pathways such as cAMP or ERK),
leading to abnormal recall of either trauma or addiction-related associative memories.
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D1R- mediated transmission is functionally linked to downstream cAMP activity (Lauzon
et al., 2013). In the present thesis, I found that cAMP inhibition fully reversed the effects of
mPFC D1R on aversive memory blockade, but interestingly, had no effect on morphine reward
memory recall, suggesting a dissociation in the molecular substrates controlling aversion
memory recall vs. reward-related memory recall, directly in the PFC. Previous evidence has
demonstrated that the ability of mPFC D1 transmission block memory recall is due to
downstream adenosine cyclase activity, increasing cAMP and protein kinase A (PKA) levels,
which in turn increase cortical GABA interneuron activity levels (Lauzon et al., 2013; Seamans
et al., 2001). Given the fact that PFC neurons store associative memories linked to emotionally
salient events, increasing cAMP/PKA levels through D1R activation might increase levels of
feedforward inhibition on PFC pyramidal neurons, thereby attenuating the ability to recall an
associative fear memory. Interestingly, in contrast to the present findings, Lauzon et al. (2013)
reported that PFC cAMP inhibition blocked the recall of morphine CPP following a standard 8day morphine CPP conditioning experiment. However, these differences may be due to
experimental paradigm differences. First, Lauzon et al. (2013) used a longer term (8 day)
morphine CPP paradigm with a supra-threshold conditioning dose of morphine (5 mg/kg) and
rats did not go through a fear conditioning procedure prior to CPP training. In addition, as we
have demonstrated in our first experiment, recalling fear memory potentiated morphine reward
salience, which in turn may make morphine reward CPP memory more resistant to recall
inhibition. In addition, the novel behavioural paradigm we used in this project examined the
direct connection between a fear memory and morphine sensitivity, it is possible that the input of
other molecular activities is required in this behavioural model. Interestingly, Lauzon et al. (2013)
also reported that cAMP inhibition failed to block a morphine priming induced CPP memory
recall (only spontaneous memory recall), which is indeed, consistent with the present findings
showing that cAMP signaling may be only partially responsible for morphine-related memory
processing.
DA D1 and D4 transmission in the PFC is known to produce biphasic effects. Thus,
whereas D1 transmission increases intrinsic inhibitory tone, D4 transmission increases the
excitability of PFC neurons and feedforward output (Seamans et al., 2001). In our experiments,
we observed similar results, demonstrating that in the subthreshold fear conditioning condition,
increased PFC D4 transmission potentiated the salience of normally non-salient fear stimuli, as
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well as potentiated the rewarding salience of the sub-threshold conditioning dose of morphine.
Given the fact that D4Rs are found on both interneurons and the pyramidal neurons, with a
preferential location on the GABA interneurons in the mPFC, it is not surprising these receptors
are functionally positioned to modulate neuronal activity by mediating local interneuron
feedforward levels (Seamans et al., 2001; Wang et al., 2003). Specifically, D4R activation has
been shown to reduce GABA interneurons activity, causing a net decrease in the inhibitory
interneuron output as well as potentiation of PFC pyramidal neurons activity levels concomitant
with increasing AMPA receptor expression levels (Yuen & Yan 2009). Given the wellestablished role of AMPA receptor-mediated transmission in learning and memory as well as
synaptic plasticity, it is perhaps the ability of PFC D4R activation to potentiate AMPA PFC
transmission and/or modulate the magnitude of excitatory inputs from other brain areas, such as
the VTA and BLA is responsible for the potentiation of associative emotional stimuli salience.
Thus, increasing PFC D4R activities might facilitate the acquisition of both aversive and
rewarding associative memories, as suggested by the present findings. Using in vitro and in vivo
techniques Onne, Wang, Lin and Grace (2005) and Laviolette et al. (2005) both reported that
blocking D4R results in alterations in PFC pyramidal neuron activity levels through GABA
transmission, as well as blocking the formation of associative memory related to cue-paired foot
shock.
In contrast with our findings with subthreshold fear learning, we found that PFC D4R
stimulation resulted in blunting the learning of a salient fear stimuli during supra-threshold fear
conditioning but did not interfere with the potentiation of morphine CPP. Some possible reasons
for this might due to the ability of D4 transmission to decreased CaMKII phosphorylation levels
in higher neuronal activity states, which in turn might block formation of normally salient
associative fear memories as previously reported (Lauzon et al., 2009). Interestingly, we found
that D4R activation induced blocking of supra-threshold fear memory did not block the
potentiation of morphine reward salience. In this experiment, we observed potentiated morphine
rewarding salience even though the formation of the fear memory had been blocked by D4R
activation. The reasons for this dichotomy are not clear, however one possibility is that given
that supra-threshold fear conditioning would expect to induce a state of high PFC neuronal
activity and inhibition of CaMKII levels, the presence of exogenous opioid molecules may have
increased mesocorticolimbic DA transmission, thus overriding the effects of decreased CaMKII
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levels in the PFC. Alternatively, morphine-induced increased DA transmission to other brain
areas (e.g. the BLA or nucleus accumbens) may be able to compensate for the effects of PFC
CaMKII reduction associated with the blockade of fear memory formation, allowing for the
formation of associative opiate reward memories, independently of fear memory processing.
Regardless, this data, similar to the findings observed with concomitant cAMP inhibition and
D1R activation, suggests a functional dissociation between PFC D4R activation and the
potentiation of morphine reward salience, in the context of supra-threshold fear conditioning.
Future studies are required to more precisely delineate the underlying mechanisms responsible
for these dissociable effects.
4.2 mPFC D1R and D4R transmission: functional links to ERK1/2 and CaMKII activity
states
A series of western blot analyses were conducted to explore the possible effects of D1R
or D4R activation on total and/or phosphorylation state changes in the ERK1/2 or CaMKII-
signaling pathways directly in the PFC. First, we found that intra-PFC D1R activation
significantly increased phosphorylation levels of ERK1/2, as well as the pERK/tERK ratio.
These findings are consistent with previous reports showing that D1R agonist activation with
SKF81297 can increase ERK1/2 phosphorylation in the striatum and the mPFC, whereas D2R
activation has no effect (Xue et al., 2015). Research has also shown that psychostimulants which
act as indirect DA agonists, such as cocaine or amphetamine, potently increase ERK1/2
phosphorylation levels in the mPFC as well as other brain areas, such as the striatum. (Fumagalli
et al., 2009; Mao et al., 2013; Valjent et al., 2004). Thus, ERK1/2 phosphorylation states are
known to be modulated through a D1R-dependent pathway. We therefore examined the possible
mechanistic role of ERK signaling in our observed behavioural effects of D1R activation to
determine if inhibiting ERK1/2 signaling may reverse the effects of D1R activation on aversive
memory recall and morphine reward sensitivity. Interestingly we found that pharmacological
ERK1/2 inhibition with U0126, fully reversed the effects of mPFC D1R stimulation on both
rewarding and aversive memory recall inhibition, such that co-administration with the ERK
inhibitor blocked D1R mediated suppression of fear memory recall and the subsequent formation
of a morphine reward CPP, demonstrating a functional role between intra-PFC D1R activation
and control of both aversive or rewarding memory recall effects. We also observed that ERK1/2
inhibition alone was able to partially restore the recall of fear-related memory, but had no effect
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on the processing of morphine-related reward memory. These findings are consistent with
previous behavioural pharmacological studies. For example, Valjent et al. (2006) reported that
administration of the ERK1/2 inhibitor U0126 blocked the recall of previously robust cocaine
reward CPP. Gholizadeh et al. (2013) further illustrated that intra- BLA and intra- mPFC local
inhibition of ERK1/2 blocked the recall of recent and remote morphine CPP, respectively. In
addition, research has reported that ERK1/2 regulates fear memory processing, as stress-related
cues induce hyper-phosphorylation of ERK1/2 whereas blocking ERK1/2 was shown to inhibit
the behavioural manifestation of conditioned fear responses (Cestari et al., 2013; Yang, Huang &
Hsu, 2004). Thus, given the fact that the ERK1/2 pathway is involved in both reward and fear
memory processing, it is not surprising that blocking this pathway impaired subject’s ability to
retrieve emotional memory as observed in both fear and reward conditioning processes. In
contrast to our observed effects on ERK 1/2 phosphorylation states, both PFC D1R and D4R
activation produced slight, but significant decreases in total levels PFC ERK 2, while D4R
activation caused a slight but significant decrease in PFC ERK 1 expression levels. Nevertheless,
changes in total ERK 1/2 expression levels mediated by PFC D4R signaling do not appear to
modulate ERK 1/2 phosphorylation states as we observed no concomitant changes in PFC D4Rmediated ERK 1/2 phosphorylation levels. While beyond the scope of the present thesis, future
studies are required to more fully explore the possible functional effects of D4R activation on
total ERK 1/2 expression levels within the PFC.
In addition to our findings with the ERK 1/2 pathway, we observed significant increases
in CaMKII- signaling selectively following mPFC D4R stimulation. Specifically, we observed a
significant and selective increase in PFC expression levels of pCaMKII-with no corresponding
changes in total CaMKII- expression level.Pharmacological inhibition of the phosphorylation
process by treatment with a selective CaMKII phosphorylation inhibitor, AIP, reversed the
effects of D4R activation in the subthreshold fear conditioning and morphine CPP paradigms.
Based upon the ability of D4R activation to increase pCaMKII- during subthreshold fear
conditioning, the present results suggest that CaMKII is a plausible molecular mechanism
underlying D4R- mediated potentiation of non-salient fear and rewarding stimuli. Notably,
treatment with the CaMKII inhibitor alone failed to potentiate fear and rewarding memory
acquisition, which suggests that pCaMKII itself is not sufficient to facilitate the acquisition of
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emotional memory; rather, consistent with in vitro work from Gu & Yan (2004), intra-mPFC
CaMKII signaling is believed to depend upon the functional input of D4R substrates for the
regulation of perceived emotional memory salience.
4.3 Role of the VTA in PFC-mediated modulation of fear and reward memory processing
Given the importance of connectivity between the PFC and VTA in the mediation of both
fear and reward-related associative memory (Lauzon et al., 2009; Bishop, Lauzon, Bechard,
Gholizadeh & Laviolette, 2011), we examined if our observed modulation of PFC D1R and D4R
transmission on opiate reward sensitivity may be mediated directly in the VTA. Decades of
research have established the important role of the mesocorticolimbic DA system in processing
the initial rewarding effects of opioid drugs (Fields & Margolis, 2015). Similar to the effects of
systemically administered morphine, we found that infusions of a subthreshold conditioning dose
of morphine directly in the VTA, was similarly modulated by intra-PFC D1R and D4R
transmission. Thus, activation of PFC D1R transmission blocked the recall of an aversive fear
memory and prevented the potentiation of sub-reward threshold morphine directly in the VTA.
In contrast, potentiating the emotional salience of non-salient fear conditioning stimuli with PFC
D4R activation potentiated the normally non-reward effects of intra-VTA morphine,
demonstrating the importance of the PFC-VTA pathway in DAergic modulation of opiate-related
reward salience. Previous work in our lab has demonstrated the important functional connectivity
between the PFC and VTA in modulating opiate-related reward salience. For example, Bishop et
al., (2011) found that pharmacological blockade of NMDA receptor signaling in the rat PFC was
able to strongly potentiate sub-reward threshold conditioning doses of intra-VTA morphine. In
addition, as previously noted, neuronal sub-populations within the PFC are capable of encoding
the associative morphine rewarding memory during CPP conditioning (Sun et al., 2011).
Nevertheless, future experiments are required to more precisely characterize how DAergic
transmission modulation of fear-related associative memories in the PFC can directly modulate
sub-cortical DAergic reward sensitivity in the VTA. For example, how does PFC D1R or D4R
activation modulate either VTA inputs to the PFC or by contrast, the control of descending PFC
to VTA projections? Alternatively, future studies are required to explore how intra-PFC D1R or
D4R modulation regulate functional outputs from the VTA to other reward-related brain
processing regions, such as the BLA or nucleus accumbens.
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4.4 Implications for understanding PTSD and addiction comorbidity
The present series of experiments reveals several novel mechanisms by which intra-PFC
transmission through the D4R or D1R can simultaneously modulate the recall and salience of
emotionally traumatic associative fear memories, and concomitantly regulate sensitivity to the
rewarding salience of opiates. Overall, an important implication for these findings is that the PFC
requires an optimal level of DA signal transduction in order to appropriately regulate both the
salience and recall of emotionally salient memories, regardless of reward or aversion valence.
Aberrant mPFC D1 transmission may result in disruptive and spontaneous memory recall
associated with catastrophic events or euphoric drug experiences, serving as a possible common
mechanism underlying the pathology of PTSD and addiction. Interestingly, PTSD has been
extensively studied with clinical populations and several reports have indicated abnormally high
level of urinary and plasma DA metabolites as well as abnormal levels of cAMP, suggesting that
abnormalities in DAergic transmission may be a common clinical feature in PTSD (Hamner &
Diamond, 1993; Lerer et al., 1987; Yehuda et al., 1992). PFC D1 transmission is highly
implicated in rewarding memory and addiction behaviours and behavioural neuroscience
research has demonstrated a unique role for mPFC D1 signaling in drug-related learning and
memory (Self et al., 1996). Notably, Lauzon et al. (2013) indicated that in the context of both
aversive and rewarding associative memory, the ability of mPFC D1 transmission is limited to the
recall stage of memory formation without impacting the stability of the original memory trace.
Thus, abnormal memory expression linked to either traumatic experiences or addiction-related
reward experiences may share a common link to aberrant cortical D1R transmission and
downstream signaling through the ERK 1/2 molecular cascade.
In contrast to the effects of D1R transmission in the recall phase of memory processing,
the present study confirmed the functional role of PFC D4R transmission during the acquisition
phase of emotional memory formation. Considerable research has highlighted the role mPFC D4
transduction and its downstream signalling pathway, CaMKII, in various neuropsychiatric
disorders, such as PTSD, addiction, schizophrenia and ADHD (Lauzon & Laviolette, 2010). The
role of intra-PFC D4R transmission in these neuropsychiatric disorders is believed to be due to
the ability of cortical D4R transmission to potently modulate the emotional salience of incoming
sensory information and associative memory formation. Abnormal signalling through PFC D4R
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substrates has been shown to lead to the misinterpretation of emotional meaning and salience of
sensory information resulting in the amplification of normally non-salient emotional stimuli and
improper assignment of motivational salience to associative memory cues. In other cases,
hyperactive mPFC D4 transduction leads to an inability to form associative memory which are
vital for survival and/or proper cognitive functions. More importantly, mPFC D4 and CaMKII
mediate the appropriate categorization of sensory information and cues based upon their
emotional salience, enabling the individual to accurately recognise the meaning of associative
cues and to respond appropriately to the environment. In the case of PTSD and addiction, the
above processes become aberrant, with patients inappropriately assigning emotional salience to
normally neutral/unimportant cues causing misguided attention, pathological ideation and
abnormal behavioural output. Thus, consistent with previous findings, the present data suggests
that cortical D4R transmission during the acquisition/encoding phase of either aversion or
reward-related associative memory, may be a functional mechanism underlying the emotional
memory pathology present in both PTSD and addiction.
4.5 Future Directions
Although the present series of studies revealed critical new roles for cortical PFC D1R
and D4R transmission in the acquisition and recall of both fear and reward-related memory
formation, there are several important questions that remain to be answered.
First, we found dissociations both between the effects of cAMP signaling and D1R
transmission in terms of modulation of fear memory recall and the subsequent regulation of
morphine reward sensitivity. Importantly, future experiments should address how and why
cAMP appears to selectively modulate the recall of fear (trauma)-related memory, but is
independent of the modulation of reward-related memory. Interestingly, we found that ERK 1/2
phosphorylation was capable of regulating the recall of both fear and morphine-reward related
memory formation, suggesting that D1R transmission via the ERK 1/2 signaling pathway may
transcend and control the processing of both aversion and reward-related emotional memory
formation. Future studies may focus specifically on examining the potential mechanistic links
between D1R, cAMP and ERK 1/2 signaling in the context of both fear and reward-related
memory processing.
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The current study demonstrated that fear memory recall leads to heightened sensitivity to
morphine’s rewarding effects, revealed in a robust CPP to a dose of morphine that normally
produces no rewarding effects. Since the CPP tests took place 24h after the last conditioning
phase, which examined only temporally recent morphine reward memory formation, it is not
clear how long lasting and/or persistent these potentiated morphine-related associative memories
may be. Thus, it would be interesting in future studies to perform extinction memory tests to
explore the memory decay curves of morphine-related associative reward memories, in order to
gain deeper insight regarding the comorbidity between PTSD and addiction and how traumatic
memories may modulate addiction related memory processing and resistance to abstinence over
the longer term. In addition, possible dynamic interactions between fear and rewarding memory
extinction curves would be of interest for future studies to gain better insight into how traumatic
and/or reward-related associative memories may interact with one another in a temporal manner
following initial memory formation.
In terms of opiate exposure states and their relevance to addiction-related memory
formation, a limitation of the present study is that experiments used only drug naïve subjects to
test their sensitivity to subthreshold morphine reward salience. Thus, it would be very
informative to investigate if and how opioid dependent rats react to sub-reward conditioning
doses of morphine differently than opiate-naïve subjects. Since opioid dependent states produce
different impacts on neural substrates, including D1, D2 and ERK 1/2 and CaMKII signaling
pathways (Lyons et al., 2013; Rosen et al., 2016), further research should be done in opiatedependent subjects during long-term withdrawal/abstinence periods.
5. Conclusions
The findings in this thesis reveal several important new insights regarding how the recall
of emotionally traumatic memories may directly impact upon vulnerability to the rewarding
effects of drugs of abuse. Specifically, the data in this thesis provides novel information
regarding how alterations in cortical DAergic transmission through D1R-ERK 1/2 or D4RCaMKII signaling mechanisms may not only strongly modulate the acquisition and recall of
associative fear-related memory, but how these mechanisms may simultaneously regulate
sensitivity to opiate-related drug reward salience. Given the high comorbidity observed between
PTSD and drug abuse liability, particularly, opioid abuse, these findings reveal unique and
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promising new directions for the future development of pharmacological and molecular
interventions that might be able to target the neurobiological links between PTSD emotional
memory pathology and addiction liability.
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